LOWERING HEALTHCARE COSTS FOR ALL AMERICANS: AN EXAMINATION OF HEALTH INSURANCE AFFORDABILITY

Committee on Energy and Commerce · Subcommittee on Health House January 22, 2026

Witnesses (6)

  • Stephen J. Hemsley, Chairman and Chief Executive Officer, UnitedHealth Group
  • Answers to submitted questions\1\ David Joyner, President and Chief Executive Officer, CVS Health
  • Answers to submitted questions\1\ Gail Boudreaux, President and Chief Executive Officer, Elevance Health
  • Answers to submitted questions\1\ David Cordani, Chairman and Chief Executive Officer, The Cigna Group
  • Answers to submitted questions\1\ Paul Markovich, Chief Executive Officer and President, Ascendiun
  • Answers to submitted questions\1\ Ellen Allen, Resident of Pinch, West Virginia

From the witness list in the published hearing record.

Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.

- LOWERING HEALTHCARE COSTS FOR ALL AMERICANS: AN EXAMINATION OF HEALTH INSURANCE AFFORDABILITY

[House Hearing, 119 Congress]
[From the U.S. Government Publishing Office]

 LOWERING HEALTHCARE COSTS FOR ALL AMERI-
 CANS: AN EXAMINATION OF HEALTH INSUR-
 ANCE AFFORDABILITY
=======================================================================

 HEARING

 BEFORE THE

 SUBCOMMITTEE ON HEALTH

 OF THE

 COMMITTEE ON ENERGY AND COMMERCE
 HOUSE OF REPRESENTATIVES

 ONE HUNDRED NINETEENTH CONGRESS

 SECOND SESSION

 __________

 JANUARY 22, 2026

 __________

 Serial No. 119-55
 
[GRAPHIC NOT AVAILABLE IN TIFF FORMAT] 

 Published for the use of the Committee on Energy and Commerce

 govinfo.gov/committee/house-energy
 energycommerce.house.gov
 
 __________
 
 U.S. GOVERNMENT PUBLISHING OFFICE
63-596 PDF WASHINGTON : 2026
=======================================================================
 
 COMMITTEE ON ENERGY AND COMMERCE

 BRETT GUTHRIE, Kentucky
 Chairman
ROBERT E. LATTA, Ohio FRANK PALLONE, Jr., New Jersey
H. MORGAN GRIFFITH, Virginia Ranking Member
GUS M. BILIRAKIS, Florida DIANA DeGETTE, Colorado
RICHARD HUDSON, North Carolina JAN SCHAKOWSKY, Illinois
EARL L. ``BUDDY'' CARTER, Georgia DORIS O. MATSUI, California
GARY J. PALMER, Alabama KATHY CASTOR, Florida
NEAL P. DUNN, Florida, Vice PAUL TONKO, New York
 Chairman YVETTE D. CLARKE, New York
DAN CRENSHAW, Texas RAUL RUIZ, California
JOHN JOYCE, Pennsylvania SCOTT H. PETERS, California
RANDY K. WEBER, Sr., Texas DEBBIE DINGELL, Michigan
RICK W. ALLEN, Georgia MARC A. VEASEY, Texas
TROY BALDERSON, Ohio ROBIN L. KELLY, Illinois
RUSS FULCHER, Idaho NANETTE DIAZ BARRAGAN, California
AUGUST PFLUGER, Texas DARREN SOTO, Florida
DIANA HARSHBARGER, Tennessee KIM SCHRIER, Washington
MARIANNETTE MILLER-MEEKS, Iowa LORI TRAHAN, Massachusetts
KAT CAMMACK, Florida LIZZIE FLETCHER, Texas
JAY OBERNOLTE, California ALEXANDRIA OCASIO-CORTEZ, New York
JOHN JAMES, Michigan JAKE AUCHINCLOSS, Massachusetts
CLIFF BENTZ, Oregon TROY A. CARTER, Louisiana
ERIN HOUCHIN, Indiana ROBERT MENENDEZ, New Jersey
RUSSELL FRY, South Carolina KEVIN MULLIN, California
LAUREL M. LEE, Florida GREG LANDSMAN, Ohio
NICHOLAS A. LANGWORTHY, New York JENNIFER L. McCLELLAN, Virginia
THOMAS H. KEAN, Jr., New Jersey
MICHAEL A. RULLI, Ohio
GABE EVANS, Colorado
CRAIG A. GOLDMAN, Texas
JULIE FEDORCHAK, North Dakota
 ------ 

 Professional Staff

 MEGAN JACKSON, Staff Director
 SOPHIE KHANAHMADI, Deputy Staff Director
 TIFFANY GUARASCIO, Minority Staff Director
 Subcommittee on Health

 H. MORGAN GRIFFITH, Virginia
 Chairman
DIANA HARSHBARGER, Tennessee, Vice DIANA DeGETTE, Colorado
 Chair Ranking Member
GUS M. BILIRAKIS, Florida RAUL RUIZ, California
EARL L. ``BUDDY'' CARTER, Georgia DEBBIE DINGELL, Michigan
NEAL P. DUNN, Florida ROBIN L. KELLY, Illinois
DAN CRENSHAW, Texas NANETTE DIAZ BARRAGAN, California
JOHN JOYCE, Pennsylvania KIM SCHRIER, Washington
TROY BALDERSON, Ohio LORI TRAHAN, Massachusetts
MARIANNETTE MILLER-MEEKS, Iowa MARC A. VEASEY, Texas
KAT CAMMACK, Florida LIZZIE FLETCHER, Texas
JAY OBERNOLTE, California ALEXANDRIA OCASIO-CORTEZ, New York
JOHN JAMES, Michigan JAKE AUCHINCLOSS, Massachusetts
CLIFF BENTZ, Oregon TROY A. CARTER, Louisiana
ERIN HOUCHIN, Indiana GREG LANDSMAN, Ohio
NICHOLAS A. LANGWORTHY, New York FRANK PALLONE, Jr., New Jersey (ex 
THOMAS H. KEAN, Jr., New Jersey officio)
MICHAEL A. RULLI, Ohio
BRETT GUTHRIE, Kentucky (ex 
 officio)
 C O N T E N T S

 ---------- 
 Page
Hon. H. Morgan Griffith, a Representative in Congress from the 
 Commonwealth of Virginia, opening statement.................... 2
 Prepared statement........................................... 4
Hon. Diana DeGette, a Representative in Congress from the State 
 of Colorado, opening statement................................. 7
 Prepared statement........................................... 9
Hon. Brett Guthrie, a Representative in Congress from the 
 Commonwealth of Kentucky, opening statement.................... 11
 Prepared statement........................................... 13
Hon. Frank Pallone, Jr., a Representative in Congress from the 
 State of New Jersey, opening statement......................... 15
 Prepared statement........................................... 17

 Witnesses

Stephen J. Hemsley, Chairman and Chief Executive Officer, 
 UnitedHealth Group............................................. 19
 Prepared statement........................................... 22
 Answers to submitted questions\1\
David Joyner, President and Chief Executive Officer, CVS Health.. 43
 Prepared statement........................................... 45
 Answers to submitted questions\1\
Gail Boudreaux, President and Chief Executive Officer, Elevance 
 Health......................................................... 47
 Prepared statement........................................... 49
 Answers to submitted questions\1\
David Cordani, Chairman and Chief Executive Officer, The Cigna 
 Group.......................................................... 57
 Prepared statement........................................... 59
 Answers to submitted questions\1\
Paul Markovich, Chief Executive Officer and President, Ascendiun. 69
 Prepared statement........................................... 71
 Answers to submitted questions\1\
Ellen Allen, Resident of Pinch, West Virginia.................... 77
 Prepared statement........................................... 79

----------

\1\ The witnesses' replies to submitted questions for the record have 
been retained in committee files and are available at https://
docs.house.gov/Committee/Calendar/ByEvent.aspx?EventID=118890.

 Submitted Material \2\

Inclusion of the following was approved by unanimous consent.
List of documents submitted for the record
Statement of Elizabeth Mitchell, President and Chief Executive 
 Officer, Purchaser Business Group on Health, January 22, 2026
Statement of Tyler Dever, Principal, Federal Government 
 Relations, National Federation of Independent Business, January 
 22, 2026
Statement of Lisa Bercu, Senior Director of Health Policy, and 
 Samantha Sears, Senior Manager of Health Policy, National 
 Consumers League, January 22, 2026
Statement of the Federation of American Hospitals, January 22, 
 2026
Statement of Patrick Giam, President, American Society of 
 Anesthesiologists, January 22, 2026
Letter of January 22, 2026, from Riva Singh, Senior Vice 
 President of Policy, American Medical Informatics Association, 
 to House Ways and Means Committee and Subcommittee on Health, 
 House Committee on Energy and Commerce
Statement of American College of Cardiology, January 22, 2026
Statement of Ilyse Schuman, Senior Vice President, Health and 
 Paid Leave Policy, American Benefits Council, January 22, 2026
Letter of January 22, 2026, from Jen Brull, Board Chair, American 
 Academy of Family Physicians, to Mr. Guthrie, et al.
Statement of American Hospital Association , January 22, 2026
Letter of January 22, 2026, from Richard Rosato, President, and 
 Elizabeth Shapiro, Interim Executive Director, American Dental 
 Association, to Mr. Guthrie, et al.
Letter of January 22, 2026, from Jess Wysocky, Director, Health 
 Care Policy, and Jake Kuhns, Vice President, Domestic Policy, 
 National Association of Manufacturers, to Mr. Griffith and Ms. 
 DeGette
Statement of Lauren Aronson, Executive Director, Campaign for 
 Sustainable Rx Pricing, January 22, 2026
Statement of Partnership for Employer-Sponsored Coverage, January 
 22, 2026
Statement of David Merritt, Senior Vice President of External 
 Affairs, Blue Cross Blue Shield Association, January 22, 2026
Article of November 3, 2026, ``UnitedHealth pays its own 
 physician groups 17% more than outside ones, study shows,'' by 
 Tara Bannow, STAT News
Statement of AHIP, January 22, 2026
Statement of the Association of American Medical Colleges, 
 January 22, 2026
Letter of January 7, 2026, from Nancy A. LeaMond, Executive Vice 
 President and Chief Advocacy and Engagement Officer, AARP, to 
 House Speaker Mike Johnson and House Minority Leader Hakeem 
 Jeffries
Article of September 30, 2025, ``ACA Marketplace Premium Payments 
 Would More than Double on Average Next Year if Enhanced Premium 
 Tax Credits Expire,'' by Justin Lo, et al., KFF
Statement of Margaret A. Murray, Chief Executive Officer, 
 Association for Community Affiliated Plans, January 22, 2026
Statement of American Cancer Society Cancer Action Network, 
 December 10, 2025

----------

\2\ Submitted material has been retained in committee files and is 
contained in the Documents for the Record at https://docs.house.gov/
meetings/IF/IF14/20260122/118890/HMTG-119-IF14-20260122-SD003.pdf.
Statement of American Hospital Association, January 22, 2026
Statement of American Lung Association, January 8, 2026
Article of January 27, 2025, ``Claims Denials and Appeals in ACA 
 Marketplace Plans in 2023,'' by Justin Lo, et al., KFF
Article of September 11, 2025, ``Congress Must Preserve Access to 
 Affordable Marketplace Coverage,'' by Lindsey Copeland, 
 Medicare Rights Center
Article of October 15, 2025, ``Damage From Inaction On ACA Tax 
 Credits Has Begun And Will Grow With Further Delays,'' by Jason 
 Levitis, et al., Center on Health Insurance Reforms
Article of October 2025, ``Eligibility Cliff on ACA Tax Credits 
 Would Make Health Care Unaffordable for Middle-Class 
 Families,'' by Jason Levitis, et al., Urban Institute
Fact sheet of the American Hospital Association, ``Enhanced 
 Premium Tax Credits,'' July 2025
Statement of Families USA, January 8, 2026
Statement of the Center on Budget and Policy Priorities, November 
 3, 2026
Letter of January 7, 2026, from Elizabeth S. Watson, Director of 
 Federal Government Affairs, AFSCME, to Members of the House of 
 Representatives
Article of December 4, 2025, ``How to Evaluate Proposals to 
 Address Expiring Premium Tax Credit Enhancements,'' by Jennifer 
 Sullivan, Center on Budget and Policy Priorities
Article of September 19, 2025, ``Older Adults Face Spike in 
 Health Insurance Costs as ACA Tax Credits Expire,'' AARP
Letter of September 15, 2025, from Amer Medical Association, et 
 al., to House Speaker Mike Johnson, et al.
Statement of Keep Americans Covered, January 20, 2026
Article of February 18, 2025, ``A proposed law could force 
 California health insurers to explain claim denials,'' by 
 Christine Mai-Duc, KFF Health News
Article of July 29, 2025, ``Marketplace Enrollees Tell Congress: 
 Extend the Enhanced Premium Tax Credits,'' by Claire Heyison, 
 Center on Budget and Policy Priorities
Letter of November 18, 2025, from Jon Godfread, President, 
 National Association of Insurance Commissioners, to Senate 
 Majority Leader John Thune, et al.
Letter of January 22, 2026, from Shawn Gremminger, President and 
 Chief Executive Officer, Nationall Alliance of Healthcare 
 Purchaser Coalitions, to Mr. Griffith, et al.
Letter of January 22, 2026, from Bari Talente, Executive Vice 
 President, Advocacy and Healthcare Access, National Multiple 
 Sclerosis Society, to Mr. Guthrie, et al.
Article of October 30, 2025, ``Older Adults at Risk if ACA 
 Subsidies Expire,'' by Lindsey Copeland, Medicare Rights Center
Statement of Merith Basey, Chief Executive Officer, Patients for 
 Affordable Drugs NOW, January 22, 2026
News release of December 4, 2025, KFF
Letter of August 21, 2024, from Alpha-1 Foundation, et al., to 
 House Speaker Mike Johnson, et al.
Statement of American College of Emergency Physicians, January 8, 
 2026
Statement of Families USA, November 5, 2025
Article of January 6, 2026, ```Bullshit'-The New Way Health 
 Giants Hide Billions,'' Hunterbook
Statement of Lauren Aronson, Executive Director, Campaign for 
 Sustainable Rx Pricing, January 22, 2026
Statement of David Merritt, Senior Vice President of External 
 Affairs, Blue Cross Blue Shield Association, January 22, 2026
Statement of Mary B. Dwight, Senior Vice President and Chief 
 Policy and Advocacy Officer, Cystic Fibrosis Foundation, 
 January 22, 2026

 
 LOWERING HEALTHCARE COSTS FOR ALL AMERICANS: AN EXAMINATION OF HEALTH 
 INSURANCE AFFORDABILITY

 ---------- 

 THURSDAY, JANUARY 22, 2026

 House of Representatives,
 Subcommittee on Health,
 Committee on Energy and Commerce,
 Washington, DC.
 The subcommittee met, pursuant to call, at 9:45 a.m., in 
the John D. Dingell Room 2123, Rayburn House Office Building, 
Hon. H. Morgan Griffith (chairman of the subcommittee) 
presiding.
 Members present: Representatives Griffith, Harshbarger, 
Bilirakis, Carter of Georgia, Crenshaw, Joyce, Balderson, 
Miller-Meeks, Cammack, Obernolte, James, Bentz, Houchin, 
Langworthy, Kean, Rulli, Guthrie (ex officio), DeGette 
(subcommittee ranking member), Ruiz, Dingell, Kelly, Barragan, 
Schrier, Trahan, Veasey, Fletcher, Ocasio-Cortez, Auchincloss, 
Carter of Louisiana, Landsman, and Pallone (ex officio).
 Also present: Representatives Latta, Hudson, Weber, Allen, 
Pfluger, Evans, and Fedorchak.
 Staff present: Marjorie Connell, Director of Archives; 
Jessica Donlon, General Counsel; Sydney Greene, Director of 
Finance and Logistics; Jay Gulshen, Chief Counsel, Health; 
Annabelle Huffman, Clerk, Health; Megan Jackson, Staff 
Director; AT Johnson, Special Advisor; Daniel Kelly, Press 
Secretary; Sophie Khanahmadi, Deputy Staff Director; Jonathan 
Kupperman, Professional Staff Member, Health; Brayden 
Lacefield, Special Assistant; Sarah Meier, Counsel and 
Parliamentarian; Joel Miller, Chief Counsel; Lillian Noland, 
Staff Assistant; Seth Ricketts, Special Assistant; Jake Riith, 
Staff Assistant; Chris Sarley, Member Services/Stakeholder 
Director; Emma Schultheis, Policy Analyst, Health; James 
Stursberg, Professional Staff Member, Health; Timothy Trimble, 
Staff Assistant; Matt VanHyfte, Communications Director; Jane 
Vickers, Press Assistant; Katie West, Press Secretary; Nick 
Wooldridge, Professional Staff Member, Health; Lydia Abma, 
Minority Policy Analyst; Jacquelyn Bolen, Minority Counsel; 
Keegan Cardman, Minority Staff Assistant; Waverly Gordon, 
Minority Deputy Staff Director and General Counsel; Tiffany 
Guarascio, Minority Staff Director; Perry Hamilton, Minority 
Deputy Director, Member Services and Outreach; Brent 
Langellier, Minority Health Fellow; Una Lee, Minority Chief 
Counsel, Health; Gayle Mauser, Minority Health Advisor; Andrew 
Souvall, Minority Director of Communications, Outreach, and 
Member Services; Hannah Treger, Minority Staff Assistant; 
Laurel Uhomba, Minority Health Fellow; Kyle Wolf, Minority 
Press Intern; and C.J. Young, Minority Deputy Communications 
Director.
 Mr. Griffith. The subcommittee will come to order.
 Before we begin, I would like to take a moment to address 
the guests in our audience.
 First of all, thank you for coming. We think engaged 
citizens are a welcome and valuable part of this political 
process.
 I do want to remind our guests in the audience that the 
Chair is obligated under the rules of the House and the rules 
of the committee to maintain order and preserve decorum in the 
committee room. I know that we all have deep feelings on these 
issues and that we may not agree on everything, but I ask that 
we all abide by these rules and be respectful of our audience 
members, our viewers, our witnesses, and, of course, members of 
the committee.
 The Chair appreciates the audience's cooperation in 
maintaining order as we have a full discussion on these 
important issues.
 The Chair recognizes himself now for 3 minutes for an 
opening statement.

OPENING STATEMENT OF HON. H. MORGAN GRIFFITH, A REPRESENTATIVE 
 IN CONGRESS FROM THE COMMONWEALTH OF VIRGINIA

 Today, we will discuss healthcare costs and patient access 
challenges by examining affordability across the entire health 
insurance marketplace.
 This hearing builds on work Republicans have done in this 
Congress to address healthcare affordability. We plan to have 
future hearings with other leaders and experts across the 
healthcare continuum to understand the root causes of rising 
healthcare costs.
 Specifically, this hearing will focus on the role insurers 
play in the delivery of care.
 The insurance market is dominated by a handful of Fortune 
50 companies that control the majority of the national market. 
In some States, a single insurer may even control 80 or 90 
percent of a particular market.
 The biggest health insurers today often manage several 
facets of the healthcare supply chain, such as owning the 
pharmacy benefit managers, the group purchasing organizations, 
multiple provider groups, and specialty or mail-order 
pharmacies.
 Even with owning those, complicated benefit designs, narrow 
networks, prior-authorization requirements, and opaque coverage 
decisions often leave patients feeling like they are paying 
more for less. The market also lacks transparency, and it is 
not easily navigable.
 One contributor to health insurance unaffordability for 
millions of Americans is the so-called Affordable Care Act, 
also known as Obamacare, that was signed into law in 2010.
 When Democrats passed Obamacare without Republican support, 
they sold the bill on the promises that premiums would fall, 
competition would rise, and if you like your insurance plan, 
you can keep it.
 Instead, Obamacare has increased healthcare costs, warped 
incentives, federalized benefits, restricted plan design, and 
limited access to care. Many patients have fewer plan choices 
than they did before Obamacare was enacted. In fact, a 
constituent of mine told me recently that his family only had 
one provider option in the Obamacare exchanges.
 Therefore, Obamacare coverage is not translating to patient 
or taxpayer affordability.
 Unfortunately, employer-sponsored insurance is also 
becoming unaffordable, and, each year, more American small 
businesses choose not to offer health insurance because it is 
too costly. This impacts the ability for a small business to be 
competitive and to attract talent.
 We know two things are true: Competition and--we know two 
things are true: Competition is essential for patient access. 
Lack of competition and consolidation within the insurance 
marketplace has led us to higher healthcare costs as a whole.
 The healthcare system needs to work for patients. That 
means empowering individuals with real choices, transparent 
prices, and coverage that fits their needs. We must strive to 
have more competitive plan options that reward quality and 
focus on affordability, access, and outcomes.
 Our discussion today is meant to move beyond politics and 
spur debate about how we can work toward delivering meaningful, 
innovative solutions for the Americans that we all serve. We 
owe it to patients to get to the root cause of the challenges 
we see across the health sector.
 And I look forward to hearing from our witnesses.
 [The prepared statement of Mr. Griffith follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] 
 
 Mr. Griffith. I now recognize the subcommittee ranking 
member, Representative DeGette, for her 3-minute opening 
statement.

 OPENING STATEMENT OF HON. DIANA DeGETTE, A REPRESENTATIVE IN 
 CONGRESS FROM THE STATE OF COLORADO

 Ms. DeGette. Thank you, Mr. Chairman.
 Americans know that healthcare is far too expensive. As it 
takes up a greater percentage of our economy than any other 
developed country, Americans' health outcomes lag far behind 
others, with our life expectancy now falling behind Spain, 
Panama, and Oman. And millions of Americans who get insurance 
on the individual marketplace saw their premiums shoot up, 
doubling on average, at the beginning of the year.
 Because of the ACA, now the lowest number of Americans ever 
are uninsured. Right now, there are 21 million people enrolled 
in the marketplaces under the ACA. But because Congress failed 
to extend the enhanced premium tax credits, healthcare coverage 
is shooting up.
 Now, 2 weeks ago today, the House did the right thing by 
passing a 3-year extension of these critical tax credits, even 
as the Republican leadership worked against it. Just 17 House 
Republicans joined Democrats to do the right thing and help 
millions of Americans--like our witness Ellen Allen, who is 
sitting right here today--continue to afford health coverage, 
and just 1 Republican on this subcommittee voted for 
affordability.
 The enhanced premium tax credits we enacted into law 5 
years ago were predicated on a simple premise: No American 
should have to pay more than 8.5 percent of their income for 
health insurance.
 But even when people do have coverage, good care can still 
be a fight to get through denials, prior-authorization 
requirements, and sky-high copays and deductibles that create 
additional barriers between America's patients and the care 
that they need.
 Just last year, this majority's top priority was to enact 
massive tax cuts for the wealthy, for people just like the 
insurance CEOs who are sitting in front of us today. These 
handouts to the rich were funded by cutting healthcare for 
hardworking Americans.
 In the same bill--in the same bill with the tax cuts--this 
majority chose not to extend premium assistance for middle-
class Americans, causing healthcare costs to skyrocket. And 
that is what has led now to this current crisis.
 In the big picture, the chairman and I can agree: What we 
need is access to quality, affordable healthcare for every 
American. That is why, frankly, I have long supported a 
solution like Medicare for All. But Americans need relief now, 
and we need immediate action to bring down healthcare costs in 
this country.
 Open enrollment for 2026 ended a week ago, as the 
Republicans in Congress failed to pass any legislation to make 
healthcare coverage more affordable. We are simply out of time.
 The Senate must act immediately to join House Democrats and 
the 17 courageous House Republicans to send this critical help 
for middle-class Americans to Donald Trump's desk, and he must 
sign it. To do anything else is to accept a poorer and sicker 
America.
 On a positive note, Mr. Chairman, I have 15 seconds left, 
and I want to thank the majority for finally including the 
health extenders package that we were supposed to pass over a 
year ago and which DOGE cut. Finally it is going to be 
included, and it is going to help get research and healthcare 
to millions of Americans.
 [The prepared statement of Ms. DeGette follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Ms. DeGette. Thank you, and I yield back.
 Mr. Griffith. Does that mean we can count on your vote this 
afternoon? Rhetorical question.
 Ms. DeGette. Good.
 Mr. Griffith. I now recognize the chairman of the full 
committee, the gentleman from Kentucky, Chairman Guthrie.

 OPENING STATEMENT OF HON. BRETT GUTHRIE, A REPRESENTATIVE IN 
 CONGRESS FROM THE COMMONWEALTH OF KENTUCKY

 Mr. Guthrie. Thank you. Thank you, Chairman Griffith.
 And I want to thank our panel of CEO witnesses for being 
here today.
 Today's hearing is the first in a series of hearings 
focused on healthcare affordability. And we begin by hearing 
testimony from our Nation's top health insurance CEOs.
 According to CMS, America spent $5.3 trillion on healthcare 
in 2024. That represents a staggering 18 percent of our 
country's gross domestic product.
 Over 200 million people in the U.S. get their health 
insurance through the private marketplace. Of that total, 
around 178 million people receive their coverage through their 
employer and 24 million get their coverage through Obamacare.
 Across these markets, healthcare costs have been increasing 
at an unprecedented rate. In the Obamacare markets, healthcare 
premium increases for 2026 were as high as 40 and 50 percent. 
In the employer marketplace, year-over-year cost increases for 
2026 are at a 15-year high. Despite what my Democrat friends 
would have the American people believe, healthcare 
affordability is far from a one-market issue.
 It also isn't a new issue. This committee has previously 
worked in a bipartisan way to pass major reforms across the 
healthcare sector to make healthcare more affordable for all 
Americans.
 I hope we can rise above the politics and have a real 
discussion about the root causes of affordability and how we 
can help all Americans have access to more affordable care.
 And that is why we have convened this panel of CEOs today 
who can speak authoritatively on the market forces affecting 
affordability.
 The goal of this hearing is to have a conversation about 
these rising healthcare costs, and your companies sit at the 
center of our healthcare financing system. Nearly every dollar 
spent on healthcare in America runs through your companies or 
one of your competitors. And we, as a country, are spending a 
lot on healthcare.
 A core component of your industry's value proposition is 
working on behalf of Americans to lower the cost of healthcare, 
along with improving access and quality. Yet healthcare costs 
are increasing every year, and more and more Americans have 
become frustrated by the feeling that their insurance isn't 
working for them and working against their health.
 I want to be clear in what we expect to hear answers on 
today:
 As some of the largest companies in our economy and amongst 
the companies that benefit the most from government subsidies, 
how do you justify the continuing skyrocketing costs for your 
beneficiaries?
 What are you doing that is working to lower healthcare 
costs, and what isn't working? And what are the barriers we 
need to address?
 What should insurance companies be doing better to live up 
to your promises to the American people?
 I thank you all for being here. I look forward to a 
spirited discussion and great information.
 [The prepared statement of Mr. Guthrie follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Guthrie. And I will yield back.
 Mr. Griffith. The gentleman yields back.
 I now recognize the ranking member of the full committee, 
Representative Pallone, for his 3-minute opening statement.

OPENING STATEMENT OF HON. FRANK PALLONE, Jr., A REPRESENTATIVE 
 IN CONGRESS FROM THE STATE OF NEW JERSEY

 Mr. Pallone. Thank you, Chairman.
 Today, Republicans are looking for a scapegoat to blame for 
the fact that 24 million Americans saw their healthcare 
premiums skyrocket at the beginning of this year. By calling 
health insurance executives before us today, Republicans are 
attempting to divert attention from their failure to extend the 
Affordable Care Act's enhanced premium tax credits.
 Make no mistake, congressional Republicans and President 
Trump are to blame for the healthcare affordability crisis 
Americans are experiencing today. And it is only going to get 
worse. That is because Republicans are sabotaging our Nation's 
healthcare system, driving up costs, taking away coverage, and 
undermining access to care at every turn.
 As a result of Republicans' actions, including passage of 
their cruel Big, Ugly Bill, 50 million people will be left 
uninsured, driving up healthcare costs for everyone with 
private health insurance.
 Now Republicans are proposing further dismantling the ACA 
in favor of junk insurance and health savings accounts that 
won't help when you or your family get sick. Chairman Griffith 
talked about ``competition,'' but it is not competition if your 
alternative doesn't provide coverage.
 For example, a policy without hospitalization, which a few 
years ago Republicans were advocating. You could buy a policy 
without hospitalization. That is not healthcare coverage.
 If I get a policy that has a deductible of $7,000 or $8,000 
and then you give me $2,000 in a health savings account, that 
doesn't help me either unless I am rich. Their policy is for 
the rich guy, not for the average guy.
 We set up the ACA because people couldn't buy health 
insurance that covered--that had good coverage and was 
affordable. And nothing Republicans have discussed so far 
changes that.
 If costs go up--which is what they have done because, you 
know, of the health crisis and the cost of healthcare--then the 
only way to help people is to provide more subsidies or tax 
credits so they can afford the insurance.
 Giving them junk insurance or giving them high deductibles 
and some kind of $2,000 amount of money for a health savings 
account isn't going to help them. It is not going to provide 
any real competition or alternative, and it is not the way to 
make healthcare more affordable.
 So I appreciate the opportunity to hear from the executives 
of our Nation's largest health insurance companies today.
 This is not your fault. This is the Republicans' fault. It 
is not your fault. Don't let them drag you in here and blame 
you for what is going on. It is not your fault.
 Democrats stand ready to continue to fight to lower 
healthcare costs for the American people.
 We have a witness today, Ellen Allen, who joins us here 
from West Virginia, and we will hear her story about how 
healthcare premiums have skyrocketed this year as a result of 
Republicans' inaction just as she is preparing for retirement.
 Americans like Ellen deserve to have peace of mind that 
they can afford the healthcare they need and their life savings 
won't be drained if they get a life-threatening disease or have 
a health emergency.
 Unfortunately, the Republicans' assault against quality and 
affordable health insurance puts that at risk. It is not going 
to help Ellen Allen.
 [The prepared statement of Mr. Pallone follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Pallone. Thank you, Mr. Chairman. I yield back.
 Mr. Griffith. The gentleman yields back.
 We now conclude with Member opening statements.
 The Chair would like to remind Members that, pursuant to 
committee rules, all Members' opening statements will be made a 
part of the record.
 We want to thank our witnesses for taking their time to 
testify before the subcommittee today.
 Although it is not the practice of this subcommittee to 
swear in witnesses, I would remind our witnesses that knowingly 
and willfully making materially false statements to the 
legislative branch is against the law under Title 18, section 
1001 of the United States Code.
 You will each have an opportunity to give an opening 
statement followed by questions from Members.
 Our witnesses today are Stephen Hemsley, CEO, UnitedHealth 
Group; David Joyner, chairman and CEO, CVS Health; Gail 
Bordeaux--Boudreaux--sorry, I will get it right--president and 
CEO, Elevance Health; David Cordani, president, CEO, and 
chairman of the board of The Cigna Group; Paul Markovich, 
president and CEO, Ascendiun; and patient advocate Ellen Allen.
 Per committee custom, each witness will have the 
opportunity for a 5-minute opening statement, followed by a 
round of questions from Members.
 The light on the timer in front of you will turn from green 
to yellow when you have 1 minute left and then to red when your 
time is up.
 I now recognize Mr. Stephen Hemsley for 5 minutes to give 
his opening statement.

 STATEMENTS OF STEPHEN J. HEMSLEY, CHIEF EXECUTIVE OFFICER, 
UNITEDHEALTH GROUP; DAVID JOYNER, CHAIRMAN AND CHIEF EXECUTIVE 
 OFFICER, CVS HEALTH; GAIL BOUDREAUX, PRESIDENT AND CHIEF 
EXECUTIVE OFFICER, ELEVANCE HEALTH; DAVID CORDANI, CHAIRMAN AND 
CHIEF EXECUTIVE OFFICER, THE CIGNA GROUP; PAUL MARKOVICH, CHIEF 
 EXECUTIVE OFFICER AND PRESIDENT, ASCENDIUN; AND ELLEN ALLEN, 
 EXECUTIVE DIRECTOR, WEST VIRGINIANS FOR AFFORDABLE HEALTH CARE

 STATEMENT OF STEPHEN J. HEMSLEY

 Mr. Hemsley. Thank you, Chairman Guthrie, Ranking Member 
Pallone, Chairman Griffith, and Ranking Member DeGette. Members 
of the committee, thank you for inviting me to testify today.
 Every day, people count on our company not just to help 
them when they are sick but to help keep them healthy and well 
at every stage of their lives. And we take that responsibility 
seriously.
 Mr. Griffith. Sir, could you move the mic a little closer 
to your mouth so everybody can hear you?
 Mr. Hemsley. Thank you.
 Like all of you, we are dissatisfied with the status quo in 
healthcare and know we must all do better. And so we are 
committed to doing exactly that. And that is in part why I 
returned to UnitedHealth Group as chief executive.
 Our mission as a company is to help people live healthier 
lives and to help the health system work better for everyone--
better outcomes, better experiences, lower costs.
 Achieving these goals means being candid about why 
healthcare costs continue to rise. The cost of healthcare 
insurance fundamentally reflects the cost of healthcare itself. 
It is more an effect than a cause. If insurance costs are going 
up even as we compete aggressively against other companies, it 
signals rising costs of health services and drugs and rising 
volumes of care activity. And it is a fact, hospital and drug 
spending has soared at three times the rate of inflation since 
before 2000.
 We limit these pressures as much as possible. We continue--
we use negotiations, data insight, better care coordination to 
moderate the cost growth, improve outcomes, and protect access. 
And we focus on preventative care so people get care before a 
condition worsens or before becoming sick at all.
 Insurance is the only sector in healthcare incentivized to 
help keep the cost of care as low as possible while still 
seeking high-quality health outcomes for people and helping 
them avoid getting sick in the first place. And it is a 
virtuous circle. Generally, the healthier people are, the fewer 
health resources they need.
 We are innovating to make high-quality healthcare easier to 
find, simpler to navigate, and, most importantly, more 
accessible and affordable. Last year alone, we negotiated 
nearly $300 billion in savings for our customers. Without those 
efforts, recent premium increases would easily have been twice 
as high.
 Nearly 90 percent of our premiums go to direct medical 
care, including in Affordable Care Act plans. Our enterprise 
margins are around 5 percent, with Medicare, Medicaid, and ACA 
margins being far less than that.
 Additionally, we have made notable progress in areas such 
as value-based care, which incentivizes better care and health 
outcomes and simplifies the experience, and in Medicare 
Advantage, which provides lower total costs than traditional 
Medicare with more benefits and lower overall costs to seniors, 
a majority of whom choose it each year.
 We have introduced innovative health plans that offer 
people the information they need up front, enabling them to 
comparison shop for care. These plans often have no deductibles 
and no coinsurance, and members pay, on average, more than 50 
percent less in out-of-pocket costs compared to traditional 
plans. And employers offering these transparent plans are also 
seeing lower total costs.
 We are committed to extending these consumer-centric 
features wherever we can to consumers, give them more choice, 
more control, more transparency and certainty, and more value.
 We are mindful of the current moment and the debates about 
affordability in Congress and throughout the country, and we 
appreciate the current bipartisan talks focused on ideas around 
affordability, transparency, and possible short-term tax-credit 
extensions.
 Because we want to continue to be part of the solution with 
respect to ACA individual plans, we will voluntarily eliminate 
and rebate our profits this year for these coverages.
 I know there are aspects of our products and services that 
are still confusing and complicated for people. We are 
intensely focused on setting a new standard of transparency, 
simplicity, and ongoing improvement as we continue taking costs 
out of the system and making healthcare more affordable.
 In addition, we have provided policy ideas in our written 
testimony intended to lower premiums, address rising health 
costs, and better align what we pay for healthcare with the 
rest of the world.
 We look forward to our discussions today about what more 
can be done to improve affordability and expand the 
availability of quality care.
 Thank you.
 [The prepared statement of Mr. Hemsley follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Griffith. The gentleman yields back.
 I now recognize Mr. Joyner for his 5-minute opening.

 STATEMENT OF DAVID JOYNER

 Mr. Joyner. Thank you.
 Chairman Griffith, Ranking Member DeGette, and members of 
the committee, thank you for the opportunity to share our 
perspective on the drivers of healthcare costs and the market 
and policy solutions needed to address them.
 CVS Health engages with millions of Americans every day in 
their communities, helping families struggling with an often 
confusing, disconnected system and the rising cost of 
healthcare. What is driving this cost is understood: greater 
demand for care, growing medical provider cost, and 
persistently high prices for hospital care and prescription 
drugs.
 Every day, we are addressing the fragmentation and the 
underlying cost of care. It starts by making care for Americans 
accessible and affordable and, most importantly, simplifying 
the patient experience at every point. Our 300,000 employees 
across the country work every day to meet this moment.
 CVS Health supports the committee's goal of addressing 
rising medical costs, and we want to be a partner in addressing 
these challenges together.
 We are working to ensure our members have access to the 
right care at the right cost. And we are expanding low-cost 
primary care, covering preventative care at no cost to 
patients, and offering free virtual care to eliminate barriers 
to access.
 We are leading the industry in developing new solutions to 
lower cost, investing in technology to identify health problems 
before they become serious, and tailoring treatment to 
individual patient needs.
 Today, I will share four ways we are making care more 
affordable and accessible.
 First, we are expanding access to coverage that rewards 
providers for keeping patients healthy.
 Second, we are reducing administrative burden, so instead 
of filling out forms, doctors can spend that time caring for 
patients, all while driving lowered administrative cost of 
care.
 We know denial of care is a major frustration for patients 
and their doctors, so we continue to reduce the number of 
claims subject to prior authorization. And by independent 
measures, we have the fewest number of services subject to it.
 When we do receive an authorization request, 77 percent are 
approved in near realtime, and that number is growing. The 
medications, nearly half are approved immediately, and for 
others the average approval times have decreased from 3 hours 
in 2024 to just 34 minutes today.
 CVS Health's bundled approach now gives providers one 
approval covering medical procedures like repeat imaging and 
medications for specific conditions. For patients undergoing 
breast cancer treatment, that means a single authorization for 
the entire series of procedures.
 Third, we are using competition to address rising drug 
costs. We are aggressively promoting the use of biosimilars. We 
now have the vast majority of members paying zero dollars out 
of pocket for the once-pricey drugs that have generated more 
than $1.5 billion in savings for our customers.
 Fourth, we are building a modern consumer healthcare 
platform that we will open to all plans and providers. For 
patients, it is simple: open one app that allows them to own 
and manage their own healthcare. For our 17 million monthly 
active app users, we will schedule appointments, refill 
prescriptions, access preventative care--all in one place--with 
the goal of helping them stay healthier at lower costs. For the 
healthcare system, it is a shared foundation we believe will 
make healthcare more coordinated and affordable.
 I took this role 15 months ago because I wanted to help 
shape the future of healthcare in this country. I am proud of 
the work we have done so far to simplify the healthcare 
experience and make healthcare more affordable and accessible 
for American families.
 I know there is much to do. It requires health plans, 
providers, and employers working together. That is why we 
support reforms that increase transparency, competition, and 
innovation, particularly among hospitals and in the 
pharmaceutical supply chain.
 We encourage policymakers to preserve flexibility for 
employers to offer benefits that meet their workforce needs and 
to avoid policies that reduce competition or add bureaucracy.
 We want to work together to, first, explore solutions that 
bring younger and healthier people into the risk pools.
 Secondly, expand the definition of preventative care to 
services that keep people healthy and out of the hospital, and 
allow people in high-deductible plans to access these services 
in their predeductible phase.
 Third, address the bad actors who are gaming the No 
Surprises Act. Centralizing eligibility, automating processes, 
and increasing oversight can help address this abuse.
 Fourth, accelerate the interoperability of health records 
to reduce friction and help patients manage their health.
 And, finally, pass the ECAPS legislation, allowing 
pharmacists to practice at the top of their license and receive 
Medicare reimbursement. This will benefit every pharmacy in 
this country while improving access for patients and reducing 
costs.
 We welcome the committee's partnership in these efforts as 
we continue to work to make healthcare more affordable for all 
Americans.
 Thank you, and I look forward to your questions and to the 
additional hearings in this series.
 [The prepared statement of Mr. Joyner follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Griffith. Thank you very much.
 I now recognize Ms. Boudreaux.

 STATEMENT OF GAIL BOUDREAUX

 Ms. Boudreaux. Thank you, Chairmen Griffith and Guthrie, 
Ranking Members DeGette and Pallone, and members of the 
committee.
 I am Gail Boudreaux, president and CEO of Elevance Health. 
For over 80 years, we have served individuals, families, and 
communities.
 I appreciate the opportunity to be with you today on an 
issue that is weighing on households across the country: 
healthcare affordability.
 Families are frustrated by the rising cost of healthcare, 
and they are right to be. Rising premiums and out-of-pocket 
costs strain household budgets and cause people to delay care. 
This is personal, and for many families it is frightening.
 We can all do better. Americans want solutions, and we are 
taking concrete steps to deliver them.
 Our responsibility is to provide coverage people can 
afford, provide clear information in plain language about 
coverage and costs, and make timely decisions. That includes 
negotiating for fair prices that affect premiums and out-of-
pocket costs.
 Our role isn't just to explain costs, it is to act and make 
healthcare easier to navigate for patients and doctors. Every 
redundant step and paperwork delay adds costs and frustrations 
without improving care.
 Prior authorizations apply to about 3 percent of our 
claims, and since January 1st of 2024 we have removed more than 
400 services from prior-authorization requirements. For what 
remains, we are expanding electronic prior authorization to 
reduce paperwork and speed decisions and using technology, 
including AI, to handle routine steps and move information 
faster, while clinical judgment remains in human hands.
 The United States now spends more than $5 trillion a year 
on healthcare. Health insurance premiums are primarily shaped 
by medical care and drug costs and where care is delivered. 
When the prices charged for care rise, premiums and out-of-
pocket costs rise too.
 Hospital spending increased by nearly 10 percent in 2023 
and again in 2024, the fastest rate in more than three decades, 
outpacing inflation and wage growth. Prescription-drug spending 
grew nearly 8 percent in 2024 and now represents a quarter of 
what employers spend on healthcare.
 Costs also rise when the same service is billed at a much 
higher price in a hospital setting than in a physician office 
or urgent care. Fraud, improper billing, and administrative 
requirements also add costs that ultimately show up in 
premiums.
 We are focused on practical solutions that lower costs and 
make healthcare easier to navigate. Our approach of 
coordinating medical and pharmacy benefits is helping employers 
lower medical and prescription-drug costs, saving some 
employers up to $212 per person per month, underscoring our 
whole-health approach.
 We also promote preventative care so problems can be caught 
early. And we work with doctors and hospitals to help patients 
get the right care at the right time and in the right setting. 
For example, our concierge care oncology program has lowered 
chemotherapy-related hospital admissions by more than 60 
percent.
 We are committed to being part of the affordability 
solution, because when healthcare is too expensive, people 
delay care, employers struggle to offer coverage, and families 
lose peace of mind.
 Keeping care within reach requires commonsense reforms that 
address root causes, such as hospital price growth, rising 
prescription-drug prices, unnecessary paperwork, and a lack of 
transparency. With discipline and partnership, progress is 
possible.
 Thank you again for the opportunity to be here. I look 
forward to your questions and to working with you to make 
healthcare more affordable.
 [The prepared statement of Ms. Boudreaux follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Griffith. I thank you.
 We are going to hold for just a second, and I am going to 
make a housekeeping announcement.
 We are expecting votes at 10:30. The ranking member and I 
will do our questions, and then we will recess until after the 
vote is completed. But we will start--as soon as we have the 
ranking member and myself and a majority of the subcommittee 
here, we will start with questions again in order to meet our 
time deadlines.
 That being said, I now recognize Mr. Cordani for his 5 
minutes.

 STATEMENT OF DAVID CORDANI

 Mr. Cordani. Chairman Guthrie, Chairman Griffith, Ranking 
Members Pallone and DeGette, and members of the subcommittee, 
thank you for the opportunity to testify here today on one of 
the most pressing challenges facing American families and 
employers, which is the cost of healthcare.
 My name is David Cordani, and I serve as the chairman and 
CEO of The Cigna Group. We are a global health service company. 
We serve millions of Americans through employer-sponsored 
coverage and union-based coverage programs, and our services 
are designed to improve affordability, broaden access, and make 
care easier to navigate.
 And while I am proud of the work we do, we know there is 
more to be done. At a high level, there are three areas where 
we could further improve the U.S. healthcare system for the 
benefit of patients.
 First, we must focus more resources on the patient earlier 
in the care journey, especially programs that prevent chronic 
disease and support long-term health.
 Second, we need to better align incentives for providers 
and pharmaceutical manufacturers that reward based on the 
clinical outcomes, not just the volume of services that are 
consumed.
 And third, we must further leverage competition in America 
where it has proven to lower costs and improve care for the 
benefit of patients.
 I joined Cigna more than 30 years ago, and during that time 
I have seen amazing advancements in medical care. Over that 
time I have also seen medical costs continue to rise at 
multiples of inflation. And, as discussed, many Americans feel 
that pressure every day at the kitchen table or at the coffee 
table, which is why this discussion is so important.
 The U.S. healthcare system does generally provide quick 
access to high-quality care. But we know access is only 
meaningful if it is affordable. The system requires health 
plans, hospitals, drug manufacturers, physicians, and 
policymakers to work together, with the patient at the center.
 At Cigna, we are focused on expanding access to 
preventative care, coordinating services around patient needs, 
and increasing transparency so people better understand how 
their healthcare costs are being spent.
 But, today, our system overwhelmingly pays for care after 
people become sick. Prevention and sustained engagement are 
more the exception than the rule.
 We do know a better approach works. For people living with 
chronic conditions, we have redesigned coverage and care models 
supporting prevention and treatment adherence. This means 
eliminating or lowering out-of-pocket costs for lifesaving 
medications. It means coordinating medical, pharmacy, and 
behavioral care for the whole person. And it means giving 
patients the support they need to stay healthy and avoid costly 
complications.
 But expanding these solutions requires us to confront the 
underlying cost drivers as well. For example, since 2000, the 
cost of a hospital stay has increased 220 percent in America. 
In 2024, the median launch price of a new pharmaceutical was 
$370,000. That is up from $2,000 less than 20 years ago, or a 
12,000 percent increase. These prices put many treatments out 
of reach for individuals or employers, especially when 
competition is delayed or blocked.
 We also need to recognize there are broader forces at work 
here as well. Our population is aging, and more Americans are 
living with chronic conditions. That increases costs across the 
entire system and drives premiums up, just as increasing fuel 
prices might drive up costs across the economy more broadly.
 At Cigna, we work tirelessly to counterweight these 
pressures. Our ability to drive competition, for example, 
amongst generic drugs has led to some of the lowest generic 
drug pricing in the world. And where we can effectively harness 
competition with brand drugs, we are driving meaningful savings 
for patients. For example, we have been able to cap the cost of 
insulin at $25. We have biosimilars available to many patients 
at zero dollars out of pocket. And we are further modernizing 
prescription benefits to deliver lower costs at the pharmacy 
counter through greater transparency.
 This focus on solutions matters most for people when they 
are at their most vulnerable. For example, a cancer diagnosis 
is devastating for both the patient and the family member. We 
build care models that eliminate out-of-pocket costs and 
connect patients quickly with top specialists, supported by 
focusing, again, on outcomes, not volume. Our goal here is 
simple: Get the right care at the right time without adding 
financial stress.
 We do recognize that no single company or sector could 
solve this alone. That is why we at Cigna stand ready to work 
with Congress, this committee, and the administration more 
broadly, and partners within the healthcare sector to further 
prioritize focusing on prevention, rewarding based on value, 
not volume, and leveraging competition to further lower costs 
for the benefit of Americans.
 I look forward to your questions today. Thank you.
 [The prepared statement of Mr. Cordani follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Griffith. Thank you.
 I now recognize Mr. Markovich for his 5-minute opening.

 STATEMENT OF PAUL MARKOVICH

 Mr. Markovich. Thank you.
 Dear Chairmen Guthrie and Griffith, Ranking Members Pallone 
and DeGette, members of the committee, thank you very much for 
the opportunity to testify before you today.
 My name is Paul Markovich. I am president and CEO of 
Ascendiun, a nonprofit and the parent organization of Blue 
Shield of California.
 Our healthcare system is bankrupting and failing us. It is 
way too expensive, it is too impersonal, it doesn't cover 
everybody, it has inferior quality scores relative to other 
countries, and it is mistrusted by far too many Americans. This 
is unacceptable.
 We all are mortal, and therefore we are all going to need 
the healthcare system. When our loved ones need to access it, 
we want them to be able to afford it and they get treated the 
way they deserve to be. Our nonprofit organization describes 
this as a healthcare system that is worthy of our family and 
friends and sustainably affordable for everyone--or, simply, 
worthy of us.
 We are a long way from that ambition right now, because 
there are too many times when the participants in the 
healthcare system--health plans, hospitals, physicians, 
pharmaceutical companies, and others--put profits ahead of 
patients and are complacent about how complex, inconvenient, 
and inefficient our current system is. This leaves consumers, 
employers, and the Government financially stressed and 
frustrated with the impersonal and inconsistent service that 
they receive.
 The good news is, we can fix this--if we have the 
collective courage and conviction to do so.
 It starts by recognizing that we must fundamentally change 
this flawed system and we must all take accountability for 
doing so. We don't need more explanations as to why healthcare 
costs so much or more attempts to blame others for the 
problems. We need to enact bold reforms as soon as possible 
that force everyone in the healthcare system to improve the 
health of Americans more efficiently.
 Specifically, there are four things we need to do.
 First, ensure every American has access to a comprehensive, 
real-time digital health record that can be used to personalize 
their healthcare and take a lot of administrative cost out of 
the system.
 Second, break the ``do more, get paid more'' fee-for-
service model, and instead start paying for outcomes.
 Third, make prescription drugs accessible and affordable by 
eliminating kickbacks in the form of rebates, fees, and spread 
pricing.
 And, finally, we need to put the entire healthcare system 
on a budget. We need your help to make this a reality. While it 
is possible for the healthcare industry to adopt changes on its 
own, based on my experience, including 13 years as a CEO who 
has been trying to pursue change, I have come to the conclusion 
that the system will not fix itself. The healthcare system 
needs some tough love and clear direction, and the American 
Government is in the best position to provide both.
 I am proud of the many things that nonprofit Blue Shield of 
California has done to try and address this healthcare crisis. 
For example, to my knowledge, we are the only major health plan 
in the country to have voluntarily pledged to cap our profit at 
2 percent of revenue and have given back more than $800 million 
to our customers in the community as a result; actively 
supported legislation for the Federal Government to negotiate 
directly with pharmaceutical companies; moved to a new pharmacy 
distribution model that does not rely on a pharmacy benefit 
manager; and supported a statewide Office of Health Care 
Affordability in California, which has put the California 
industry on a budget and has the authority to enforce it.
 But, in the spirit of accountability, we have not done 
enough fast enough. The average cost of a family health 
insurance policy is now more than $27,000, or the cost of a new 
car, every year. I and we are a part of the problem with the 
unaffordable, highly flawed healthcare system we have today. 
But I am committed to doing our part to fix it.
 We have an affordability crisis. Our healthcare system is 
broken, but we are not. On behalf of Blue Shield of California, 
I am ready to work together to create a healthcare system that 
is truly worthy of us.
 Thank you.
 [The prepared statement of Mr. Markovich follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Griffith. Thank you.
 Ms. Allen, you are now recognized for 5 minutes.

 STATEMENT OF ELLEN ALLEN

 Ms. Allen. Chairs Guthrie and Griffith, Ranking Members 
Pallone and DeGette, and members of the committee, thank you 
for the opportunity to testify on the importance of the 
Affordable Care Act and the essential premium tax credits that 
make health insurance accessible and affordable for more 
Americans.
 My name is Ellen Allen. I am from Pinch, West Virginia. I 
am a daughter of Appalachia who has formally worked since I was 
15 and informally since I was 12 years old. I mowed the lawns 
of many of my neighbors and picked up discarded glass bottles--
soda bottles mostly--took them to the local grocer, and 
leveraged those for a soda pop and a Moon Pie.
 While I wasn't born into great wealth, I did enjoy the 
privilege of growing up in a middle-class working family in 
southern West Virginia. I ate well, I was dutiful to my annual 
physicals, and I took good care of myself. Still do so today.
 One of the privileges I have enjoyed throughout my life is 
access to high-quality, affordable health insurance. I am 64 
years old, and I have essentially never lived a day without 
health insurance. Until the last 3 years, I always had 
employer-sponsored health coverage.
 I changed jobs in 2023. The small organization that I work 
for today can't afford the $50,000 for the annual premium to 
cover two of its employees--two employees. I enrolled in the 
ACA in August of 2023 and remain enrolled today.
 Last month, I did what millions of Americans and tens of 
thousands of West Virginians did: I went online to re-enroll in 
my health insurance through healthcare.gov, the ACA 
marketplace. When I saw my new premium, I felt a pit in my 
stomach. While I was expecting to see an increase, it was a 
punch in the gut to see my premium had jumped 323 percent.
 In 2025, I paid just under $500 per month, nearly $6,000 a 
year, for a Bronze plan that included vision and dental. I 
liked this healthcare plan, and it was somewhat affordable even 
though I had a high deductible and $9,200 maximum out-of-pocket 
costs.
 In 2026, with the expiration of the enhanced premium tax 
credits, my monthly premium is now just under $2,000. And that 
is without vision or dental. I simply couldn't afford it. I was 
forced to drop that. And my maximum amount out-of-pocket now is 
$9,900 for this year, almost $10,000.
 Despite taking good care of myself, eating well, 
maintaining an active lifestyle, I have developed conditions 
that can be managed with medications and sometimes a more 
invasive procedure. But this means I am likely to hit my 
maximum out-of-pocket expenses.
 So far, for the first 8 months of this year--I will be 
eligible for Medicare in September--it will cost me almost 
$16,000 in premiums only. Then add 40 percent of coinsurance I 
am responsible for, and I am likely to face over $25,000 in 
healthcare-related costs for me alone. And that is just the 
first 8 months of 2026.
 This is a lot to ask of a hardworking American who has 
worked every day of her adult and teen life.
 For the last few years, millions of Americans, including 
67,000 West Virginians, have been able to afford marketplace 
coverage thanks to the enhanced premium tax credits. They kept 
people insured. They kept small business owners covered. They 
kept families healthy. The tax credits helped reduce West 
Virginians' uninsured rate from approximately 20 percent to 
below 6 percent. I think that that is an extraordinary 
achievement in healthcare.
 West Virginians know what it means to work hard and play 
fair. We expect fairness. We expect fairness. And, right now, 
there is nothing fair about a system that makes us choose 
between saving for retirement or dipping into our savings to 
pay for a procedure that is life-preserving--or, as several 
people I know are doing, they are dropping their health 
insurance altogether and rolling the dice.
 In conclusion, I just want to emphasize, this is fixable. 
Congress could act now to restore and make permanent the ACA's 
expanded premium tax credits. Doing so would save lives, 
protect families, and strengthen our economy.
 I urge this body to consider a 3-year extension of the 
credits, and during that time please work on bipartisan ways 
that truly make healthcare more accessible and affordable for 
every American in every stage of our lives.
 The expiration of the EPTCs is not an economic 
inevitability, it is a political choice.
 Healthcare is not a luxury, it is a necessity. The ability 
to access and afford coverage should never depend on how much 
money you make, where you work, or who you voted for.
 In conclusion, again, when lawmakers choose to cut taxes 
for the wealthy instead of keeping healthcare affordable for 
working families, they are choosing who wins and who loses. And 
it is clear that people like me and my fellow West Virginians 
are being asked to lose. The policy decision sacrifices our 
healthcare.
 It is time for our leaders to put people before profits, 
families before corporations, and patients before politics. 
Because when we say healthcare is a human right, it is time we 
act like it.
 Thank you again for the opportunity, and I look forward to 
your questions.
 [The prepared statement of Ms. Allen follows:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Griffith. Thank you, Ms. Allen.
 We now begin questioning.
 I ask that Members not begin a new question to our 
witnesses as their 5 minutes expire and would encourage Members 
to submit written questions for the record.
 I now recognize myself for 5 minutes.
 Ms. Allen, it is great to have you here today. You brought 
up fond memories. I too grew up in and am a son of Appalachia. 
I grew up in Virginia, on the other side of the line, and used 
to collect bottles at the waysides between Christiansburg and 
Salem, where I grew up.
 All right. Panel, as a whole, I believe competition lowers 
costs. Do any of you disagree with me that taking away the ban 
on physician-owned hospitals would increase competition in some 
provider markets? And if you do disagree, please raise your 
hand.
 Seeing none. I appreciate that.
 Well, then the question becomes, do you think there should 
be more insurance competition, or more competition in the 
insurance market, particularly in light of the fact that many 
of your companies own huge swaths of healthcare, including 
pharmacies, mail pharmacies, and PBMs?
 Mr. Hemsley, got any thoughts on that?
 Ms. DeGette. Please turn your mic on.
 Mr. Griffith. Yeah, turn your mic on.
 Mr. Hemsley. I apologize. Thank you.
 While we think it is already a very competitive market, we 
are always open to competition.
 Mr. Griffith. Yeah. The problem I have--as you may have 
heard in my opening--is that we have issues in my district 
where we, in the ACA marketplace, only have one provider. So, 
you know, there is not as much competition.
 Now, I will now ask--and, Mr. Hemsley, you might want to 
listen as well, but I am going to ask Mr. Cordani--I am aware 
of the issues that you all have had when negotiating rates in 
my district in Virginia and in east Tennessee.
 How do you reimburse larger systems versus smaller systems 
in these poor or underserved or rural areas?
 Mr. Cordani. Mr. Chairman, when you say larger versus 
smaller ``systems''--hospital systems?
 Mr. Griffith. Well, yeah. Exactly.
 Mr. Cordani. Each hospital system negotiation is unique, so 
each hospital system has its own contractual relationship, and 
we try to get to the best balance of affordability and access.
 We typically serve the employers in your home State, so we 
get the network or the access to the hospitals and the 
reimbursements to align. It is not higher reimbursement for 
larger and lower reimbursement for smaller. They are unique to 
each provider.
 Mr. Griffith. So, when you have only one provider, 
particularly in the ACA marketplace, how does that impact the 
leverage that you have when negotiating with hospitals?
 Mr. Cordani. In the broader sense, if I understand your 
question, more choice equals improved affordability, more 
competition equals improved affordability. So there is a 
consistent theme in any aspect of our business--
 Mr. Griffith. And we have a unique situation in east 
Tennessee, Mrs. Harshbarger's district, and mine, where, 
because the hospitals were all at threat, both States and the 
Federal Government allowed Ballad Health to have a monopoly. I 
think it is the only way we could have saved our hospitals, but 
how does that impact your ability to negotiate with them?
 Mr. Cordani. In general, the phenomenon you describe, Mr. 
Chairman, causes prices to go up on an accelerated basis. So 
less choice means more price inflation, whether it is through 
consolidation of hospitals or otherwise.
 Mr. Griffith. All right.
 Mr. Hemsley, the reason I asked you to pay attention is 
that we have a limited number of healthcare access in the 
region, and recently your subsidiary, Optum, bought the HMG, or 
the Holston Medical Group, which is one of the largest--it is 
the largest provider in east Tennessee and provides in 
southwest Virginia as well.
 How does that impact the ability to have competition in the 
marketplace?
 Mr. Hemsley. Well, Mr. Chairman, the motivation for that is 
to drive a value-based care system that has been described by 
me and others on the panel to actually get better care, more 
continuous care, and a better value to individuals.
 So it really plays into an effort to make sure that there's 
good resources available, that value-based care can operate and 
optimize the experience for individuals.
 Mr. Griffith. All right.
 Mr. Hemsley. And physicians get paid very effectively under 
value-based care arrangements.
 Mr. Griffith. All right. And I hate to move everybody 
along, but we are running out of time.
 Again, Mr. Hemsley, based on your company's experience, did 
the Biden administration loosen enrollment validation 
requirements on the enhanced, temporary COVID premium tax 
increases to such an extent that it led to widespread waste in 
the Federal ACA program, yes or no?
 I am specifically talking about the shadow enrollees----
 Mr. Hemsley. Oh.
 Mr. Griffith [continuing]. That you all don't even know who 
they are.
 Mr. Hemsley. We do believe that there should be real 
oversight in terms of the ACA marketplace and all marketplace 
to----
 Mr. Griffith. But the loosening up of thevalidation 
requirements led to this dilemma, did it not? Yes or no, 
because I only have 9 seconds.
 Mr. Hemsley. We believe there should be----
 Mr. Griffith. So that is a yes?
 Mr. Hemsley [continuing]. Discipline and oversight.
 Mr. Griffith. You believe that that led to an increased 
number of people who were being insured that aren't actually 
insured.
 Mr. Hemsley. We believe there should be more----
 Mr. Griffith. All right. I have to yield back and recognize 
the gentlelady from Colorado, Ms. DeGette, for her 5 minutes.
 Ms. DeGette. Thank you, Mr. Chairman.
 I want to talk a little bit about what it was like before 
the Affordable Care Act was implemented.
 Before the ACA, 14.5 percent of Americans were uninsured. 
After the ACA, it was 8.6 percent. Because of insurance costs, 
it crept up a little bit, but then after the tax credits were 
implemented, it dropped back down to 8.2 percent.
 Mr. Cordani, your company offers both ACA plans and 
administers employer-based health coverage, correct?
 Mr. Cordani. That is correct.
 Ms. DeGette. Now, prior to the ACA, private health 
insurance plans were not required to provide coverage for 
preexisting conditions like cancer or diabetes. Is that 
correct?
 Mr. Cordani. We--Madam Chair, we participate in the larger 
employer market----
 Ms. DeGette. No, no. Before that--before the ACA, the plans 
did not--were not required to cover these things, preexisting 
conditions, right?
 Mr. Cordani. In the small employer marketplace, correct. In 
the----
 Ms. DeGette. OK.
 Mr. Cordani [continuing]. Large employer marketplace----
 Ms. DeGette. Now----
 Mr. Cordani [continuing]. They were covered.
 Ms. DeGette [continuing]. Even in employer-based insurance, 
there could be restrictions like waiting periods on coverage of 
preexisting conditions before the ACA. Is that correct?
 Mr. Cordani. Congresswoman, in the small employer market--
--
 Ms. DeGette. Correct.
 Mr. Cordani [continuing]. Yes.
 Ms. DeGette. And plans were permitted to have lifetime 
benefit limits, where if you became too expensive as a patient, 
they could throw you off the insurance. Is that right?
 Mr. Cordani. Yes, it is.
 Ms. DeGette. OK.
 Now, people might have had to pay also for preventative 
services to keep them healthy before the ACA had the essential 
benefits included. Is that correct?
 Mr. Cordani. Again, in the small employer market, not in 
the large employer market.
 Ms. DeGette. OK.
 Now, today, are your plans in the ACA marketplace or 
employer plans in large or small markets permitted to engage in 
any of these practices?
 Mr. Cordani. Congresswoman, we cover approximately 1 
percent----
 Ms. DeGette. No, no. Are----
 Mr. Cordani [continuing]. Of the ACA, and, no, they are 
not.
 Ms. DeGette. I know what----
 Mr. Cordani. No, they are not.
 Ms. DeGette. I know what you do. Are people in the large or 
small markets permitted to say, ``No, you have a preexisting 
condition, I am not going to cover you''?
 There are certain requirements in the ACA that everybody 
has to follow now so that everybody can have insurance. Is that 
right?
 Mr. Cordani. That is correct.
 Ms. DeGette. OK.
 Mr. Cordani. The practices in the large employer market are 
now----
 Ms. DeGette. I get you.
 Mr. Cordani [continuing]. In the small employer market.
 Ms. DeGette. Now, the ACA has succeeded in many ways, but 
clearly--and we can agree on this on both sides of the aisle--
systemwide work is needed to bring down costs for everybody--
people on exchanges, people with employer-based insurance, 
people with Medicare, and more.
 Enhanced premium assistance built upon what the ACA got 
right. Capping the cost of premiums in the individual 
marketplaces contributed to over 24 million people purchasing 
insurance on the exchanges last year, including Ms. Allen.
 So, Mr. Markovich, I want to ask you: ACA premium support 
is calculated based on some of the lowest premiums in the 
market. Is that correct?
 Mr. Markovich. Yes.
 Ms. DeGette. Now, if one plan is more expensive, subsidies 
don't just automatically increase. Is that right?
 Mr. Markovich. That is correct.
 Ms. DeGette. OK. And that means that plans have to compete 
on price, not just sit back and let the subsidies roll in. Is 
that right?
 Mr. Markovich. Yes.
 Ms. DeGette. Now, some of my colleagues have said this 
assistance to middle-class Americans is a handout to insurers.
 Mr. Joyner, we had enhanced premium subsidies in place in 
2024. Is that right?
 Mr. Joyner. Correct.
 Ms. DeGette. Now, at that same year, the health benefit 
segment of your business took a $984 million operating loss. Is 
that right?
 Mr. Joyner. Correct.
 Ms. DeGette. And so I would say, if premium support is a 
handout, it is surely not a very good one. What premium support 
is, though, is help to the middle--is help to help the middle 
class afford healthcare.
 So I want to ask you, Ms. Allen, when people can't afford 
insurance, do you think it is worse for the person going 
without healthcare or worse for the insurance industry?
 Ms. Allen. It is--it can be catastrophic for the individual 
going without insurance or delaying the help they need.
 Ms. DeGette. So I have 45 seconds left. Some of you know 
about my daughter Francesca. She is a type 1 diabetic. And last 
summer--and she is a young lawyer--she had a job through her 
employer.
 And she called me--I was listening to you, Mr. Cordani, 
talk about the insulin prices.
 But she called me up, and she said, ``Mom, can I put my 
$1,500 quarterly diabetes equipment payment on your credit 
card? Because I am just having a little cash flow problem this 
month.'' And I said, ``$1,500 quarterly?'' She had a $6,000 
deductible on her insurance.
 So we have to fix that. You have to fix that. And you all 
have to be our patients in fixing that. Because that ain't 
going to work for Francesca, and that is sure not going to work 
for Ms. Allen or anybody else.
 I yield back.
 Mr. Griffith. The gentlelady yields back.
 By agreement, we are going to get one more set of questions 
in. I now recognize the chairman of the full committee from 
Kentucky, Mr. Guthrie.
 Mr. Guthrie. Thank you, Mr. Chairman.
 Thank everybody for being here today.
 And I want to start with: Experts, including the 
Congressional Budget Office, estimated that the expiration of 
the temporary Obamacare enhanced COVID credit is projected to 
increase premiums by anywhere 4 and 8 percent, depending on the 
market, yet in many areas for 2026 insurers requested and were 
approved for premium increases of 30, 40, even 50 percent.
 So, Ms. Boudreaux, you are in Kentucky. So the average 
Elevance Obamacare plan increased its premium by roughly 24 
percent. Despite what Democrats would have the American people 
believe, the temporary COVID credit does little to actually 
lower underlying Obamacare premiums, and the American taxpayers 
are footing the bill.
 So, Ms. Boudreaux, by your best estimation, even if the 
Democrats' temporary COVID credits were extended, would 
Obamacare plan bids in my State of Kentucky increase or 
decrease between 2026 and 2025?
 Ms. Boudreaux. Well, thank you very much for the question, 
Congressman.
 You know, as we shared, premiums reflect the underlying 
costs----
 Mr. Guthrie. So they would have increased, right? I only 
have 5 minutes, I am sorry. So they would have increased 
regardless of the extended credits, correct?
 Ms. Boudreaux. The credits will give consumers----
 Mr. Guthrie. But they still increased.
 Ms. Boudreaux [continuing]. A break, but the overall costs 
are still driven by underlying root causes--
 Mr. Guthrie. Well, let's talk about the overall costs.
 So I want to--Obamacare costs are skyrocketing, and the 
American people are holding the bag. But, unfortunately, 
because the incentives have been so warped by the Democrats' 
policies, these affordability challenges are not just happening 
in Obamacare but across all of the healthcare markets.
 And so I want to focus on a particular incentive. And I 
would like to quickly go through a few questions for each of 
the CEOs, and I really need a quick yes-or-no question.
 Does the medical loss ratio, or MLR, put in place by the 
Obamacare--does it cap the dollars that you can maintain at a 
percentage of the total amount of the premium payments your 
companies receive? Does the MLR cap what you can maintain based 
on the premium?
 Is that a yes for everyone? It does.
 Is it true that if the amount of your premiums go up, then 
the amount of dollars you can maintain, including profits, 
would actually increase? Yes or no?
 Yes, it would go up.
 Mr. Markovich. Yes.
 Mr. Guthrie. So, as premiums increase, wouldn't your 
companies' input costs, like hospital reimbursements, provider 
payments, and drug costs, increase?
 So the MLR policy also requires you to spend a set 
percentage of premiums on medical services. So, under the 
requirements of the MLR policy, the less that your companies 
contain the costs of healthcare, then the more your premiums 
increase, and that results in increasing your total profit 
potential.
 So then the Obamacare MLR policy--effectively, it is an 
incentive for your premiums to be higher, because you are 
penalized when you try to curtail health costs.
 Is that true, yes or no?
 Mr. Markovich. No.
 Mr. Guthrie. Let's start with--yeah, Mr. Hemsley? And we 
will go down.
 Mr. Hemsley. This is a very competitive marketplace. We 
compete based upon price and premiums. So it is very 
competitive. And premiums really reflect the actual cost of 
healthcare services. So----
 Mr. Guthrie. So, again, I know I have got brief time, so we 
can let each one answer, please. I am sorry.
 Mr. Hemsley. Yeah.
 Mr. Guthrie. Mr. Joyner?
 Mr. Joyner. In our specific example, Congressman, we did 
not perform well in the exchange last year, so costs actually 
exceeded the premiums we collected. So, regardless of the MLR, 
we underperformed and actually gave back money to the 
Government.
 Mr. Guthrie. OK.
 So, Ms. Boudreaux?
 Ms. Boudreaux. The MLR--we are in a highly regulated 
environment. We have to--as you know, at least 80 percent of 
premiums, the majority go to medical costs. Our loss ratio in 
2024 was 88.5 percent, and in 2025 we did not make money in the 
individual exchange.
 Mr. Guthrie. Mr. Cordani as well?
 Mr. Cordani. Mr. Chairman, we lost money in the exchange 
all but 2 years since 2014. So that phenomenon has not affected 
us favorably.
 Mr. Guthrie. Mr. Markovich?
 Mr. Markovich. We have capped our profit at 2 percent for 
the last 15 years, so this doesn't matter.
 Mr. Guthrie. So, when you get the--you have an insurance 
business and you get limited on what you can recover, then it 
encourages you to vertical integrate so you can make profits 
other places. So, if the costs are reflective of your premiums, 
then if you can capture those costs that you are paying out, 
then it gives you the opportunity.
 So, Mr. Hemsley, UnitedHealth Group has pursued aggressive 
vertical integration since the passage of Obamacare. And you 
have the largest health insurance plan, one of the largest 
PBMs, and one of the largest employer providers--employer of 
providers, and there is not a sector in which you don't have a 
presence.
 So, if competition helps healthcare, how do you explain the 
vertical integration? Does that encourage competition and 
cheaper? How do you explain the vertical integration and 
competition?
 Mr. Hemsley. It really is a very substantial value dynamic 
in terms of bringing a better care experience and more value to 
the healthcare environment in total, by better coordination of 
care across those spectrums, by better use of data, by more 
engagement in critical areas in healthcare, including how drugs 
are made available and integrated into therapies--
 Mr. Guthrie. Thanks. My time has expired, so I apologize.
 And I will yield back to the Chair.
 Mr. Griffith. I thank the gentleman for yielding back.
 I now will declare the committee in recess. We will begin 
as soon as we get a relative number back. And Ranking Member 
Pallone will be up in the queue. He is up in the batting order 
when we get back.
 Thank you.
 [Recess.]
 Mr. Griffith. All right. I am going to call the 
subcommittee to order. We are back in session.
 And I now recognize the ranking member of the full 
committee, Mr. Pallone, for his 5 minutes of questioning.
 And I am taking--getting ready to say I am taking a minute 
or two so we get a couple more Members in here before he 
finishes.
 All right. Mr. Pallone, you are recognized.
 Mr. Pallone. Thank you, Mr. Chairman.
 I wanted to turn to Ms. Allen. Just last week, President 
Trump put out his so-called Great American Healthcare Plan 
where he says we shouldn't fund ACA enhanced premium tax 
credits, and we should just give cash to people to put in tax-
exempt health savings accounts.
 So, Ms. Allen, your testimony speaks to the more than 
$25,000 in out-of-pocket healthcare costs you are facing this 
year, and that is even with becoming Medicare eligible in 
September.
 In the face of losing the ACA enhanced premium tax credits, 
would having access to a health savings account put a dent in 
your healthcare costs?
 Let's even say that the health savings account was 
preloaded with a couple of thousand dollars, which seems to be 
what the President is talking about. How does that compare to 
the reality of the healthcare costs that you are facing?
 Ms. Allen. Thank you for the question. You know, frankly, 
that is insulting. A $2,000 deposit into a health savings 
account for someone whose premium is $2,000 a month does not go 
a long way, so it wouldn't be very helpful at all.
 Mr. Pallone. My point is that the President and I think the 
Republicans are now facing the reality, they have these ideas, 
you know, which they even--some of them passed on the floor a 
couple weeks ago, the President talks about it, but they are 
not really addressing the root causes of rising healthcare.
 And the only people that I know who, you know, talk about 
this, you know, willing to do a high deductible, we hear like 
could be $7,000, $8,000 a year, and then, you know, you get a 
couple of thousand in a health savings account, are people that 
are wealthy, because you can't--it seems to me you can't, you 
know, put money into--first of all, you can't even put money 
into a health savings account unless you have some excess money 
to spare, right?
 And so this idea of, you know, highlighting a health 
savings account as an answer, it just isn't--it only benefits 
the wealthy, in my opinion, because the majority of Americans 
can't afford, you know, their medical bills, much less prefund 
a tax advantage account for thousands of dollars. It doesn't do 
anything for them. And I really think that if you want to 
address the affordability crisis now, the only answer is 
extending the ACA enhanced premium tax credits.
 But let me go back to--I don't know if we have time for 
everyone, but I wanted to ask some of the CEOs, I will start, I 
guess, with Mr. Markovich, to the companies who provide 
coverage on the ACA marketplace and ask for the plans you 
offer, what are you--what are people telling you about the 
coverage? What are you hearing from them?
 I will start with you, Mr. Markovich.
 Mr. Markovich. Well, what we are seeing is that for certain 
people in certain categories, their premiums are going up quite 
substantially as a result of the expiration of the tax credits.
 I was speaking to a member in California last week. He is 
61 years old, he is a proprietor of a small business, he has 
been a 10-year member under the ACA covering himself, his wife, 
and his two daughters, and his premiums were going to go from 
$1,600 a month to almost $5,000 a month. He simply couldn't 
afford it, and he ultimately ended up putting his wife and two 
daughters on a Bronze plan, a much less rich plan, and he is 
literally going uncovered and just trying to hang on until he 
is eligible for Medicare. So for people in that category--
higher income, 400 percent of poverty level, and that age 
bracket--it has been some significant increases.
 Mr. Pallone. And the same thing is happening in my home 
State, right? In other words, you have people whose premiums 
have doubled, tripled because of the Republicans' inaction on 
the premium tax credits. And the problem is if you go from 
Silver to Bronze, you know, you often have less coverage or you 
have a higher deductible or higher copays.
 And, you know, I just--when the Republicans say, ``Oh, that 
is OK,'' it just doesn't work for the average person. And the 
idea of having these health savings accounts to make up the 
difference is completely out of reach for people who are middle 
income. That is my experience.
 I know I can't go down the whole list here. My time has run 
out.
 Thank you, Mr. Chairman.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentlelady, vice chair of the 
subcommittee, Mrs. Harshbarger from east Tennessee.
 Mrs. Harshbarger. Thank you, Mr. Chairman. And thank you to 
the witnesses for being here today.
 Today, we are here because American families are being 
crushed by healthcare costs. And the failures of Obamacare and 
insurance companies sit at the very center of that system.
 Premiums are up, deductibles are up, choice is down, and 
meanwhile the insurance profits, consolidation, and executive 
compensation continue to rise.
 This is not a failure of doctors or patients. It is a 
failure of a system that rewards bureaucracy over care, opacity 
over transparency, and market power over competition.
 So first I want to touch on the issue of consolidation and 
vertical integration. And as a pharmacist, both in my practice 
and from healthcare providers across the country that contact 
me, there is a real concern when a single corporation controls 
coverage, pricing, dispensing, and care decisions. When that 
level of vertical integration exists, competition erodes and 
patients end up paying more. That is just the bottom line.
 There is a chart to the right of me, and what we see, this 
is what it looks like in real practice.
 [Information displayed:]

 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mrs. Harshbarger. The same corporate family decides what is 
covered, they set the drug prices and the rebates through its 
PBM, it controls the pharmacy counter, it owns the doctors and 
the clinics, and they make referrals, and it increasingly 
controls the data and analytics that drive the utilization 
decisions.
 Ladies and gentlemen. That is not competition. That is 
control. And that isn't just participating in the market. It is 
writing the rules of the market.
 So we are going to start with some questions. First Mr. 
Hemsley, and then I will go to Mr. Joyner.What prevents your 
companies from steering patients to their own pharmacies and 
clinics, prioritizing your own PBMs, or designing benefit 
structures that disadvantage competitors? And if your answer is 
simply going to be existing law or existing regulations, you 
need to pinpoint specific guardrails that affirmatively stop 
those practices.
 Mr. Hemsley.
 Mr. Hemsley. Well, thank you, Representative, for the----
 Mrs. Harshbarger. And I have got a short amount of time, so 
you need to be quick, sir.
 Mr. Hemsley. I think there are a number of factors. The 
objective here is to actually provide a better value and a 
better experience to the consumer, and there are many 
regulations and business practices that ensure that----
 Mrs. Harshbarger. OK. Well, you can submit that in writing 
to me, your answer, sir.
 Mr. Griffith. And if you could pull the mic a little 
closer. Pull the mic a little closer to your mouth so we can 
hear you.
 Mrs. Harshbarger. Mr. Joyner, same question.
 Mr. Joyner. At this point, we see the combination of 
businesses that we are in is helping solve and/or address the 
challenges in healthcare. I mean, I think people would suggest 
that technology doesn't work, there is a fragmented and 
disjointed experience, so by putting these businesses together, 
we believe we are solving for, you know, one, the 
fragmentation----
 Mrs. Harshbarger. If you are in a rural healthcare setting 
like my district or Representative Morgan Griffith's district, 
listen, you have independent pharmacies who are under water. 
They can't get reimbursed properly. They lose money on every 
prescription. You have physician practices that cannot get it 
together. They go bankrupt because of the vertical integration 
within these entities.
 So you can also submit in writing your answer to that, sir. 
Yeah.
 Mr. Hemsley, you know, I am used to following the money, 
especially when patients are told something is about 
affordability. And AARP presents itself as an independent 
nonprofit speaking for seniors, but its own financial filings 
showthat UnitedHealth paid AARP over $9 billion in a single 
deal, far more than AARP brings in from membership dues and 
more than four times its annual operating revenue.
 They also earned royalties tied directly to insurance 
premiums, meaning, more seniors pay--the more they pay, the 
more AARP makes. Yet that same organization lobbies Congress on 
affordability and pushes policies that benefit large insurers 
like yours.
 So before we accept AARP as an independent voice for 
seniors, we need some straight answers about who this 
relationship is really serving.
 So I have two questions: Why does UnitedHealth pay AARP 
roughly $9 billion, and what does UnitedHealth get in return, 
and what percentage of AARP's total revenue comes from 
UnitedHealth today?
 Mr. Hemsley. Thank you for the question, Representative. We 
have had a longstanding relationship with AARP, more than 20 
years, and we serve their members----
 Mrs. Harshbarger. Well, you are not answering my question, 
sir.
 Mr. Hemsley. Well, and we extended that for an indefinite 
time.
 Mrs. Harshbarger. Well, I am out of time, so you can submit 
your answer in writing.
 Thank you, sir, and I yield back.
 Mr. Griffith. Thank you very much. The gentlelady yields 
back.
 I now recognize the gentleman from California, Dr. Ruiz.
 Mr. Ruiz. Thank you very much.
 I am an emergency medicine physician, I work in the 
emergency department and have treated many patients and also 
many uninsured patients.
 I just want to cut to the chase and get to the effects of a 
growing population that are uninsured on to the healthcare 
system.
 Ms. Boudreaux, you said in your testimony that hospital 
pricing is a part of increasing costs. Mr. Markovich, what does 
a growing population in the millions of uninsured patients do 
to a hospital for uncompensated care?
 Mr. Markovich. Well, the dynamic is that people then--by 
law, hospitals have to accept patients that come to the 
emergency room irrespective of whether they have insurance or 
not. And then typically what happens is they don't get 
reimbursed, or they get reimbursed very little for that care, 
and then they are generally increasing or looking to find that 
revenue from other sources. And so it has----
 Mr. Ruiz. What sources do they----
 Mr. Markovich. They come back to the plans and negotiate 
higher reimbursement.
 Mr. Ruiz. So they negotiate higher reimbursements from the 
plan, and what does the plan then do in preparation for that?
 Mr. Markovich. Well, I mean, we do our best to keep the 
rates as low as----
 Mr. Ruiz. You do your best, but----
 Mr. Markovich. But, I mean, there are just many 
circumstances in which in order to serve a population, to 
provide access, you have to have these hospitals in the network 
and you end up raising your prices.
 Mr. Ruiz. So in other words, you raise the prices for 
premiums is what you just said.
 Mr. Markovich. Yes.
 Mr. Ruiz. And what happens to the individual who is 
uninsured? They no longer seek care, they can't afford the 
care, what happens to them and their health outcomes?
 Mr. Markovich. There's been studies on this. Their life 
expectancy tends to be lower. They tend to delay healthcare.
 Mr. Ruiz. So they die earlier, you are saying.
 Mr. Markovich. They die earlier, and they generally aren't 
in as good of health.
 Mr. Ruiz. So they are sicker. And when they get sick, where 
do they go? Do they see a primary care doctor, or where is 
their safety net? Do they go--the uninsured.
 Mr. Markovich. Excuse me, Congressman. They go to the 
emergency room.
 Mr. Ruiz. They go to the emergency department. The 
emergency department is one of the higher-cost places to get 
care, or is it lower cost to get care?
 Mr. Markovich. Higher.
 Mr. Ruiz. Higher cost. So they go to the hospital, higher 
cost, they are sicker, the hospital gets uncompensated care, 
they are negotiating higher prices so they can keep their doors 
open, and so you are increasing premiums. OK.
 Now, I just want to make this point clear because the 
Republicans just passed the Big Ugly Law, right, that cuts 
Medicaid up to $1 trillion, that is going to leave 15 million 
people uninsured. But they said, ``No, it is not going to 
affect anybody. We are only going to try to get--try to get 
those that are scamming the system by creating overburdened 
administrative requirements.''
 But we have argued all along that doing that is going to 
raise costs for everybody. And we just made the link that the 
uninsured population becomes uncompensated care, strains 
hospitals, they have to keep their doors open, they are going 
to put pressure on all of you during negotiations, and you will 
increase premiums.
 Do you agree, Cordani? Mr. Cordani?
 Mr. Cordani. Congressman, the phenomenon you described is 
correct.
 Mr. Ruiz. Do you agree, Ms. Boudreaux?
 Ms. Boudreaux. The phenomenon that you described is 
important, but I think----
 Mr. Ruiz. Do you agree, Mr. Joyner?
 Mr. Joyner. I agree.
 Mr. Ruiz. Do you agree, Mr. Hemsley?
 Mr. Hemsley. I agree.
 Mr. Ruiz. Every single health insurance people here is 
stating that because of the 15 million uncompensated care 
produced by the Republican Big Ugly Law, that everybody else's 
premium is going up, and this uncompensated care is going to 
cost hospitals $400 billion. OK.
 In addition to that, this Big Ugly Law reduced revenues to 
hospitals by over $600 billion. So costs are going up by $450 
billion, and the revenue has gone down by $600--over more than 
$600 billion. It is about a net loss of over a trillion dollars 
for just hospitals alone, in addition to the nearly $1 trillion 
cuts to Medicaid.
 The big issue here is the healthcare crisis that 
Republicans have created that is in--cut Medicaid in order to 
give billions in tax cuts to billionaires, and it is raising 
premiums across the board for all of those who have your 
insurance.
 And I yield back.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentleman from Florida, Mr. Bilirakis, 
for his 5 minutes of questions.
 Mr. Bilirakis. Thank you, Mr. Chairman. I appreciate it. 
Thanks for holding this hearing. It is a very critical hearing.
 Insurance companies play a significant role in our 
healthcare system, as everyone knows, and it is our duty as 
lawmakers to ensure that our families and constituents can 
access the care they need.
 I often hear from constituents who experience delays or 
denials for specialty drugs for conditions like hemophilia, 
rheumatoid arthritis, or cancer. Patients cannot deal with 
burdensome processes to re-up their medications, especially 
when missing a dose could be life threatening, or they cannot 
afford to pay thousands of dollars out of pocket.
 So first question is for Mr. Hemsley: How can we fix this 
broken system where patients often feel like they either pay 
out of pocket, if they can, or jump through hoops to access 
medication?
 Mr. Hemsley, please.
 Mr. Hemsley. Well, thank you for the question. I think it 
is a very thoughtful question. I think that we should be 
advancing and there are protections in the market that when 
people change their planned coverage, that there should be 
continuation of care.
 In the prior authorization, disciplines in the space can 
also be strengthened and improved and made in a real-time basis 
so that there isn't delay in care.
 Mr. Bilirakis. OK. A followup here, from the perspective of 
an insurance plan. Would you rather--again, for Mr. Hemsley, 
would you rather spend a dollar to pay for a patient's 
prescription that may prevent an adverse health event, or would 
you rather spend it on paying a hospital bill after an adverse 
health event takes place?
 Mr. Hemsley. A very well-framed question. Thank you, 
Representative.
 We are very much oriented to preventative care and 
proactive care and avoidance of more serious and acute 
experiences in higher-cost settings.
 Mr. Bilirakis. OK. So the answer is you would rather----
 Mr. Hemsley. Preventative care.
 Mr. Bilirakis [continuing]. Pay the prescription as opposed 
to having somebody--I mean, quality of life is so important 
too. I mean, you can't put a price on a person's life, that is 
for sure.
 Mr. Hemsley. Absolutely.
 Mr. Bilirakis. So as cochair of the Congressional Rare 
Disease Caucus, I spent years promoting policies that help 
bring innovative cures to market, and rare disease companies 
have made remarkable progress delivering these cures. I think 
most of you would agree with that.
 We know that earlier intervention with new treatments, like 
gene therapy, can give patients a second shot at life. That is 
priceless and saves money in the long run, of course.
 Cell and gene therapies could reduce total disease costs 
and productivity by up to 30 percent for certain serious 
conditions in the U.S., potentially translating to billions in 
savings, where you can't put a price on a person's life, or 
quality of life, in my opinion.
 However, we often hear that these drugs are denied by 
insurance companies due to policy exclusions or cost concerns, 
despite their overwhelming benefits.
 So second question is for Mr. Cordani. How does Cigna 
approach coverage decisions for high-cost but high-impact 
treatments like gene therapies.
 What types of innovative payment models does your company 
deploy to deliver these innovative treatments to your members 
at an accessible price?
 Mr. Cordani. Congressman, thank you for the question. Two 
parts to my answer.
 One is, the coverage policies are determined typically 
employer by employer that we serve. We serve large employers. 
We will advise them based on the clinical evidence, and the 
vast majority of the coverage that we are able to provide for 
our large employers are comprehensive coverage.
 Back to innovative programs. If you take some of the most 
expensive gene therapies, there are several that are in excess 
of $1 million per dose. We were the first offer program that 
actually took all the affordability risk away from the employer 
through our Embark Program by simply charging $1 per member per 
month because no one was able to predict when that event was 
going to transpire, but we needed to have access for the 
benefit of our employers.
 That is an example of an innovative program that removes 
the uncertainty for the employer while ensuring that access 
exists if the unique need for one of those 1-, 2-, or 3-
million-dollar pharmaceuticals are necessary.
 But getting to comprehensive coverage is typically working 
with the employers and advising them on the most comprehensive 
coverage possible.
 Mr. Bilirakis. OK, thank you very much.
 And I yield back, Mr. Chairman.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentlelady from Michigan, Mrs. Dingell, 
for her 5 minutes.
 Mrs. Dingell. Thank you, Mr. Chair. And thank you, Ranking 
Member DeGette, for holding this important and very timely 
hearing.
 It is coming at a pivotal moment. Millions of Americans 
across the Nation have seen their healthcare premiums skyrocket 
because of both the expiration of the Affordable Care tax 
credits last month--the only thing that made a lot of people 
able to afford it--but also, because of the passage, I will 
behave today and just call it the Big Brutal Bill.
 Insurers sent out renewal notices a couple months ago 
notifying consumers that their premiums were going to skyrocket 
in 2026, yet all of you are posting record profits, approving 
millions of dollars' worth of CEO compensation packages, 
executive bonuses, and paying your shareholders.
 Let me tell you something: People are really struggling. I 
hear these stories every single day. The moms are the worst. 
They are not able to get their kids their medicine. Even 
parents with asthma--their children have asthma--can't afford 
the inhalers.
 Make no mistake that we are seeing a ripple effect. My 
colleague next to me just talked about some of them that are 
going on. The American people deserve better.
 I want to start with Ms. Allen. I want to thank you for 
being here today and for your willingness to be one of the 
faces sharing your personal story. It is important for 
everybody in this country, but especially the executives at 
this table, to understand directly from real people living with 
the consequences of both what happens here in Congress and what 
happens in the insurance companies.
 Like nearly 200 million Americans, Ms. Allen is living with 
a chronic health condition that makes consistent and affordable 
coverage important.
 Ms. Allen, I know you had no choice but to buy the Bronze 
plan under the Affordable Care marketplace. You wanted to buy 
the Silver, but you couldn't afford it.
 Can you explain what that means in real terms?
 Ms. Allen. Thank you for the question so very much. Yes, I 
was hoping to purchase the Silver plan just to reduce my total 
out-of-pocket costs. I mean, 40 percent coinsurance, the out-
of-pocket costs, I know I would face $10,000 potentially, and 
actually likely.
 So that is money that I actually took out of a savings 
account to pay my healthcare costs. And I am closer to 
retirement, right, than not, so that is not helping me secure 
my economic viability in my retirement years.
 Mrs. Dingell. I am going to ask you one more question and 
then move to the others. But your Affordable Care plan that you 
have, how many--it has worked, right? How many claims have been 
denied?
 Ms. Allen. You know, I have had essentially no claims 
denied with my plan. I have been very happy with my plan, 
particularly with the tax credits.
 Mrs. Dingell. Until this year, correct?
 Ms. Allen. Until this year. I think I have had one 
specialty eye drop medication denied, which eventually I was 
able to secure.
 Mrs. Dingell. Now I would like to turn to Mr. Hemsley, who 
is the CEO of the country's largest insurer. A CBS News 
analysis of about 1.3 billion Federal health insurance claims 
across 3 years shows that in 2024 insurers denied 19 percent of 
in-network claims, about 1 in 5. UnitedHealthcare in particular 
denied as many as one third of its Federal claims in the 
preceding 2 years, all while raking in record profits of $400 
billion.
 Patients who are battling terminal illnesses are spending 
the last days and months of their lives with loved ones on the 
phones battling with their insurance company, and essential 
treatments are being denied.
 Mr. Hemsley, should sick patients who don't want to leave 
their families with bills have to spend hours on end fighting 
to get their treatments approved?
 Mr. Hemsley. Congresswoman, thank you for the question. It 
is very important that people don't go through that kind of 
complexity and that----
 Mrs. Dingell. Then how are you simplifying it because I 
don't have a lot of time.
 Mr. Hemsley. I would love to comment on that. Really only 
about less than 2 percent of all the interactions that we 
receive are under a prior authorization review, and the vast 
majority of those are administrative. And at the end of the 
day, 99 percent of all the care is covered.
 We should be doing more to expedite and make prior 
authorization processes quick, realtime, accurate, crisp, and 
not interfere with care.
 Mrs. Dingell. So are you telling me the fact that one third 
is denied is not true?
 Mr. Hemsley. It is not consistent with our experience at 
all.
 Mrs. Dingell. I have more questions for the record.
 Thank you, Mr. Chair, and I will yield back.
 Mr. Griffith. The gentlelady yields back.
 I now recognize Mr. Carter of Georgia for his 5 minutes of 
questioning.
 Mr. Carter of Georgia. Thank you, Mr. Chairman.
 Between 2014 and 2024, the seven largest for-profit health 
insurers, including United, CVS, Cigna, and Elevance, raked in 
over $10 trillion in revenue. Ten trillion dollars. And $543 
billion in profits.
 In fact, since the passage of the Unaffordable Care Act, 
the stock prices of these health insurers has increased by over 
a thousand percent. A thousand percent.
 [Information displayed:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Carter of Georgia. Premiums are rising, and patients 
struggle to afford care. Insurance executive compensation 
continues to increase at the expense of patients. Americans now 
owe--and hear me and hear me clearly--Americans now owe $220 
billion in medical debt. Two hundred and twenty billion 
dollars.
 To put it simply, the system is failing the people it's 
meant to serve, and that is the patients.
 Mr. Joyner. Mr. Joyner, in 2024, CVS Health spent a 
staggering $41 million in compensation to you and your 
colleague Karen Lynch. This is enough to cover the premiums for 
thousands of American families.
 How do you justify getting paid that much when so many of 
your patients struggle to afford skyrocketing premiums?
 Forty-one million dollars, Mr. Joyner.
 Mr. Joyner. That was--Congressman, thanks for the question.
 Mr. Carter of Georgia. Don't thank me for the question. 
Just answer them, please.
 Mr. Joyner. That was not my compensation that you 
referenced. This past year, my compensation was $17 million.
 Mr. Carter of Georgia. It was $17 million. Pardon me.
 Mr. Joyner. Of which 1.1 was my base salary. The rest is 
long-term incentives. And the bonus----
 Mr. Carter of Georgia. I just met with some pharmacists out 
there who want to say you are welcome, they helped you pay 
that--they helped pay your salary.
 Mr. Joyner. And I think it is important to note, based off 
the performance of the year, I did return my bonus back to the 
Employer Relief Fund. So the employees that were going through 
challenging and difficult times got the benefit of my bonus 
last year.
 Mr. Carter of Georgia. CVS employees?
 Mr. Joyner. Yes, sir.
 Mr. Carter of Georgia. Going through the difficult--what 
about the patients who are trying to pay their premiums going 
through difficult times?
 Let me ask you, Mr. Hemsley, yes or no--don't thank me for 
the question, just yes or no: Have you ever personally looked a 
patient in the eye and explained why your company denied them a 
medication their doctor said that was needed?
 Have you ever personally looked a patient in the eye and 
told them that?
 Mr. Hemsley. I have looked patients in the eyes many times. 
I don't recall whether it is regarding a prior authorization, 
but it is----
 Mr. Carter of Georgia. Well, Mr. Hemsley, let me tell you, 
I practiced pharmacy for 40 years, I am the one who had to look 
the patient in the eye. I am the one who had to tell them that 
on your behalf. It is not fun.
 [Photo displayed:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Mr. Carter of Georgia. Mr. Hemsley, I want to tell you a 
story about Andrea Kelly. She is a single mother from Kentucky 
who was diagnosed with stage 2 breast cancer and has endured 
years of chemotherapy, surgery and radiation just to stay 
alive, and she wants to stay alive because she has got a 7-
year-old daughter.
 Despite being stable on the medications for a year, 
UnitedHealthcare is now denying Andrea her Lupron injection and 
Veozah medication. According to her doctor, these denials are 
actively increasing--as you would imagine, and you understand--
they are actively increasing Andrea's risk of cancer 
recurrence.
 This is not about convenience or cost. This is about 
whether her cancer comes back.
 To quote Andrea, and I quote, ``I am a single mom and would 
do anything to live as long as I can for my daughter, who is 
now 7. I need access to my medication so that I can live for my 
child,'' end quote.
 It was me. I was the one who went to the counter, I was the 
one who had to tell them that. Not you. Not you, Mr. Joyner. 
Not any of you on this panel, but me, the pharmacist. I was the 
one who had to tell them that.
 Mr. Hemsley, knowing that your company's denial raises 
Andrea's risk of cancer recurrence, why is UnitedHealthcare 
overriding her doctors and denying their medication?
 Do you have any idea?
 Mr. Hemsley. I don't know that particular circumstances.
 Mr. Carter of Georgia. Can you help me out here because I 
want to help her out.
 What can I tell her? What can I tell Andrea that she can 
tell her 7-year-old daughter?
 Mr. Hemsley. I would love to learn more about that and see 
if we can't help solve that problem.
 Mr. Carter of Georgia. Let me ask you this, Mr. Hemsley. 
President Trump is proposing a bold new healthcare plan, and I 
applaud him for that, one that puts patients in control. Thank 
God somebody finally realizes instead of sending the money, my 
colleagues--instead of sending money to insurance companies, 
send it to the patients, let them create a competitive 
marketplace.
 The President is proposing this. He wants to put patients 
in control, expand choice, and ensure transparent pricing.
 Can we count on you, Mr. Hemsley, to support President 
Trump's great healthcare plan?
 Mr. Hemsley. Representative, we will be open to any kind of 
bipartisan solution, and I think the President's thoughts 
contribute to the conversation, good ideas to be considered----
 Mr. Carter of Georgia. I certainly hope so because for 40 
years I am the one. I am the one.
 Thank you, Mr. Chairman. I yield back.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentlelady from California, Ms. 
Barragan, for her 5 minutes of questioning.
 Ms. Barragan. Thank you, Mr. Chairman.
 I want to just ask the witnesses. All of you here, except 
the witness on the end--all of you get a stock option or a 
stock benefit for your compensation.
 Is that correct, Mr. Hemsley?
 Mr. Hemsley. Yes, Representative.
 Ms. Barragan. And Mr. Joyner?
 Mr. Joyner. Yes.
 Ms. Barragan. Ms. Boudreaux.
 Ms. Boudreaux. I do as well, tied to long-term incentives.
 Ms. Barragan. OK. And----
 Mr. Cordani. Yes, I do.
 Mr. Markovich. No, we don't have any ownership or stocks. 
We are a nonprofit. There is no ownership.
 Ms. Barragan. OK. You get performance bonuses instead?
 Mr. Markovich. Correct.
 Ms. Barragan. OK. So those of you who have stock, your 
company has to do better or good for you to maintain that value 
in that stock.
 Is that right? Nobody disagrees with that, right?
 [No response.]
 Ms. Barragan. You are all in the business of making a 
profit, right? Nobody disagrees with that?
 [No response.]
 Ms. Barragan. OK. Mr. Hemsley, you got a $60 million one-
time equity award. That is a lot of money. For my constituents, 
when I said we were having this hearing today, I said, ``What 
would you ask?''
 They said, ``We want to know why they are making so much 
and why we can't afford our healthcare, or why we stretch every 
penny and dime to buy healthcare just to have the claim denied 
when I actually need it.'' And that is what is wrong. That is 
what is wrong in this system.
 Mr. Hemsley, you were just asked about the denial rates. I 
have a chart.
 [Information displayed:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Ms. Barragan. I have a chart right here of the denial 
rates. I don't know if you can see it, but UnitedHealthcare 
Group, according to the Kaiser Family Foundation study, says 
your in-network denial rate is 33 percent. That is 33 percent. 
You just told my colleague that wasn't accurate.
 Are you saying the report is inaccurate, or are you just 
not aware of what your denial rates are?
 Mr. Hemsley. Representative, I think we are aware of our 
denial rates. I don't know what the context of what you are 
showing me.
 Ms. Barragan. OK. So you are not aware of the study. OK. 
Well, what do you think your denial rate is?
 Ms. DeGette. Excuse me. Can you pull the mic closer?
 Ms. Barragan. What do you think the percentage is?
 Mr. Griffith. Yeah, we are having a hard time hearing. If 
you could put your mic closer and we will give you an extra 5 
seconds.
 Mr. Hemsley. Sorry.
 Ms. Barragan. What do you think your denial a rate is?
 Mr. Hemsley. Less than 2 percent.
 Ms. Barragan. Yeah, that is wildly off from any numbers 
that I have seen.
 I want to enter into the record an LA Times article 
published in February of 2025 that tells the story of Colleen 
Henderson and her 3-year-old toddler who, of course, is insured 
by UnitedHealthcare. They fought your company for 5 years to 
pay for specialty care to treat their 3-year-old daughter's 
rare condition. She had a tumor in her bladder. A tumor in her 
bladder. The family ended up with $1 million in medical debt 
and was forced to declare bankruptcy because UnitedHealthcare 
said treatments recommended by the doctors were unnecessary.
 Do you understand why the American people are not a fan of 
UnitedHealthcare and big healthcare companies, Mr. Hemsley?
 Mr. Hemsley. I think that is a tragic situation. I don't 
know the details of it, but I am very sympathetic to situations 
like that.
 Ms. Barragan. Well, what are you going to do to make sure 
that more families are not going into medical debt, and that 
their kids can get the care they need, because you know the 
alternative is the kid is going to die.
 Mr. Hemsley. Well, I am glad you brought that up because I 
think one of the reasons that motivated me to return to this 
company is because I think we could be a force for solutions 
like that, and that we are--our mission aligns to that, and my 
purpose is to improve the performance of this enterprise to 
solve those kinds of solutions.
 Ms. Barragan. Well, I hope that we see improvements, and I 
am going to be tracking that progress to see if it actually 
happens.
 The other thing that is really quite fascinating is that we 
find that most people will not appeal these denials. Most 
people don't have the time or the effort. I live in a district 
which working-class families, they can barely find the time to 
show up to two jobs to pay their bills.
 Do you think they are going to have the time and the effort 
to appeal a claim?
 We have seen that less than 1 percent of claims are 
appealed, but when they are, insurance reverse their decision 
44 percent of the time. That is almost half.
 Why do your patients have to fight your company to get 
their claims covered?
 Mr. Hemsley. Representative, again, I appreciate the 
subject. It is important. They shouldn't have to fight. We 
should make this much easier and intuitive, and we use 
technology for that purpose. We have a number of initiatives in 
market right now to try to make it----
 Ms. Barragan. Mr. Hemsley, the way you are talking about 
this is not sympathetic. It is not compassionate. ``I 
appreciate the topic.'' These are people's lives. These are 
children's lives.
 This is where people--you said that you want to help people 
when they are sick. You know what doesn't help? When they get a 
bill, when they have to go into medical debt for $1 million of 
debt. That doesn't help people when they are sick.
 I hope that you all are going to do better.
 Mr. Griffith. The gentlelady yields back. And the 
gentlelady referenced a document. If she could make sure that 
we have a copy of that, and without objection, it is so ordered 
to be entered into the record.\1\
---------------------------------------------------------------------------
 \1\ The information has been retained in committee files and is 
contained in the Documents for the Record at https://docs.house.gov/
meetings/IF/IF14/20260122/118890/HMTG-119-IF14-20260122-SD003.pdf.
---------------------------------------------------------------------------
 I now recognize the gentleman from Pennsylvania, Dr. Joyce, 
for his 5 minutes of questioning.
 Mr. Joyce. Thank you, Mr. Chairman.
 According to CMS data from 2024 on total healthcare 
expenditures, spending reached a new high of over $5 trillion. 
Notably in this report, hospital costs, which now make up 30 
percent of that $5 trillion, are the steepest, rising costs 
being paid by the American patient. One of the reasons driving 
this has been the trend of hospital consolidation leading to 
regional monopolies dominating markets. I hope that this is a 
topic that this committee will explore in future hearings.
 For our insurers on the panel, please raise your hand if 
you agree with the following statement: Highly consolidated 
provider markets make it harder to contract at competitive 
rates for the services on behalf of your customers.
 [No verbal response.]
 Mr. Joyce. I see that Mr. Hemsley, Mr. Joyner, Ms. 
Boudreaux, Mr. Cordani, and Mr. Markovich have all raised their 
hands. Thank you.
 Since the passage of the ACA, we have seen costs across all 
markets continue to increase. One of the key issues driving 
this is the medical loss ratio, or the MLR, that requires plans 
to spend either 80 or 85 percent of their premium dollars on 
healthcare expenses.
 The MLR created multiple perverse incentives for insurance 
companies to dramatically consolidate both vertically and 
horizontally.
 The companies that you lead today are not just involved in 
insurance. You own PBMs, you own specialty pharmacies, you own 
retail pharmacies, you own GPOs, you own physician groups and 
practices. In some cases, you own hospitals and you own drug 
manufacturing companies, and at least one of you owns a bank. 
This has led to alleged cases of self-dealing as your companies 
work to circumvent the MLM requirements.
 I would like to add for the record a STAT News article from 
November of last year entitled ``UnitedHealth pays [Optum 
physicians] 17% more than outside [providers].'' Under MLM 
rules, it is now in the insurer's interest to purchase as many 
health services that count towards that 80 or 85 percent 
medical spend requirement to ensure that Americans' premium 
dollars merely are just changing hands within your company's 
corporate structure.
 [Information displayed:]

 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Since provider profits are not capped under the MLR in the 
same way that planned profits are, there is absolutely no 
incentive to keep prices low. In fact, it is in your interest 
to keep driving them even higher, resulting in bigger payments 
that can make your own corporate-owned providers bigger profits 
that you can obtain legally skirting the MLR requirements.
 As a doctor--which there are many of us on this committee--
we took the Hippocratic Oath, an oath that says, ``Above all, 
do no harm,'' but it is painfully evident that the promise that 
we took is not reflected in the blatant gaming of the MLR, 
because you are clearly putting corporate profits ahead of 
patients, and ultimately each and every one of you are hurting 
those patients.
 Transparency in this area is critical for us to truly 
understand what is driving cost increases. And I would ask that 
by the end of February, in writing, to please provide to this 
committee the names, the size of the business areas of each 
subsidiary that your company own that you have spent premium 
dollars that would qualify as a medical or quality-improvement 
expense under the MLR.
 Can you please also provide the percentage of your dollars 
spent in each individual or commercial or Medicare Advantage 
market that went to the subsidiaries that you own?
 And can you provide a breakout of how your negotiated rates 
compare for services delivered by your affiliates versus a 
nonaffiliate provider? Please raise your hand to indicate that 
you will provide the committee with that information by end of 
February.
 [No verbal response.]
 Mr. Joyce. Seeing that all of the insurers--Mr. Hemsley, 
Mr. Joyner, Ms. Boudreaux, Mr. Cordani, and Mr. Markovich--have 
all raised their hands.
 In addition, the growing physician employment that each of 
you operate, that is one problem. But you also own some of the 
largest pharmacies in our country, and this has led to a crisis 
among smaller and rural pharmacies, especially in my district 
in south central and southwestern Pennsylvania, closing and 
leaving entire communities unserved.
 I would also like you to provide in writing a comparison of 
total cost and spend for routine dispensing fees when you pay a 
community pharmacy in your network against what you pay a 
pharmacy that you own. Please raise your hand to indicate that 
you will provide this committee that information by the end of 
February.
 Mr. Joyner. Congressman, we don't all own----
 Mr. Joyce. I see all health insurers have raised their 
hands. I will follow up with questions for the record detailing 
these requests, and I ask that you stand by that commitment 
that you just made to answer these questions for my patients 
and for my constituents.
 Thank you, Mr. Chairman, and I yield back.
 Mr. Griffith. The gentleman yields back.
 The gentleman referenced a document he wanted to be placed 
in the record. If you make sure we have a copy of that, and 
without objection, it will be so ordered.\1\
---------------------------------------------------------------------------
 \1\ The information has been retained in committee files and is 
contained in the Documents for the Record at https://docs.house.gov/
meetings/IF/IF14/20260122/118890/HMTG-119-IF14-20260122-SD003.pdf.
---------------------------------------------------------------------------
 Further, I would request that since you asked for specific 
information by the end of February, if you would put that in 
writing so that it can be presented to the members who are 
insurance company executives.
 Mr. Joyce. Yes, Mr. Chairman.
 Mr. Griffith. I appreciate that. Thank you very much.
 I now recognize the gentlewoman--gentlelady from 
Washington, Dr. Schrier, for her 5 minutes of questions.
 Ms. Schrier. Thank you, Mr. Chairman. Thank you to our 
witnesses today. Thank you to Dr. Joyce for his comments. I 
wholeheartedly agree.
 I would like to talk about Medicare Advantage today, 
specifically with regard to prior authorizations. Just to set 
the stage, I am a pediatrician and took care of kids in my 
community for almost 20 years before coming to Congress.
 I also have had type 1 diabetes for over 40 years, so I get 
what it is like to be a patient who is dealing with 
difficulties with insurance companies.
 And now I am a Member of Congress and I hear a lot from my 
constituents, and I am here to go to bat for them.
 So just--I am sure it is not a news flash for you, but just 
so you know, people are pretty pissed off at their insurance 
companies because they are paying more every single year, and 
they feel like they are not getting the value for it, and, 
like, you are not living up to your end of the bargain.
 I mean, their insurance companies, your companies, are 
charging more, paying less, and then delaying or even denying 
care due to abusive demands for prior authorizations. And I 
hear the same, by the way, from hospitals, from physicians. 
They are telling me that they are forced to hire more people to 
deal with your paperwork than nurses, and that is just plain 
wrong.
 Particularly when it comes to Medicare Advantage, not only 
do you delay that care with prior authorization demands, but 
you sometimes flat out deny claims after the services are 
already rendered.
 And here is an example. One of my constituents had a 
stroke, required hospitalization. This patient had a 
UnitedHealth Medicare Advantage plan, and UnitedHealth refused 
to pay for that hospitalization because United decided that it 
was medically unnecessary, overwriting the doctor's own medical 
decision.
 And so, now we have got this senior who is in the hospital, 
can't go home, stuck with a huge bill, and that is just 
unconscionable.
 And it is shameful that you are doing this to people on 
Medicare Advantage. I mean, they paid into the system for their 
whole lives, they are paying premiums now, they are counting on 
you to look after them, and I just want you to think about how 
many elderly patients who suffered a stroke can then go home 
and deal with sitting on hold with customer service and 
submitting letters in the appeals process. And it took over a 
year, by the way, for UnitedHealth to finally pay.
 Mr. Hemsley, if a patient's physician has determined that 
their patient should be in the hospital after a stroke, why 
would UnitedHealth decline that care?
 MR. Hemsley. I am not familiar. I appreciate the question, 
and very sympathetic to the situation that you described, you 
described it before. I am not--I don't have specific 
knowledge----
 Ms. Schrier. You don't really need specifics, like, senior 
suffered a stroke, doctor said this guy is not safe to go home, 
and United overruled.
 Mr. Hemsley. They should get all the care that is 
appropriate for them, yes.
 Ms. Schrier. Thank you for saying that, and I will 
communicate that to my constituents and go to bat for them. I 
will tell you that paying a bill is the last thing patients 
should worry about after having a stroke and doing this because 
a multibillion-dollar company doesn't think that it is 
necessary for them to get their care.
 I mean, this is why so many people hate their insurance 
companies. They pay a lot of money, they expect peace of mind, 
and then the insurance company leaves them high and dry.
 A lot of you run Medicare Advantage plans, but UnitedHealth 
is the poster child for Medicare Advantage abuse. I mean, we 
all know about padding diagnoses so you can make patients seem 
sicker and riskier and then overcharge the Government for their 
care.
 But today's focus really is on prior authorizations and 
denials, which you demand more than other insurance companies 
that take care of Medicare Advantage patients. And most 
patients, they just shrug their shoulders. They give up. But 
the ones who do appeal, 80 percent of them get their appeals 
covered.
 If these denials are ultimately overturned, why are you 
doing these preauthorizations and denials?
 Mr. Hemsley. Well, I appreciate the question, 
Representative. We have been methodically reducing the area of 
prior authorization and expediting that process. We are not 
trying to do any other----
 Ms. Schrier. I am with 15 seconds. I am going to hold you 
to that, and I will follow up with you about what you are doing 
now. But I have to tell you that to the rest of us, this looks 
like your business model. It looks like you bet on wearing 
patients down, on them not appealing, and then they either 
decide to just eat the costs, or they die before they get the 
care they need.
 And my constituents are sick of it, and we are sick of it, 
doctors are sick of it, and people deserve better. So we need 
Medicare Advantage reform now.
 Thank you.
 Mr. Griffith. The gentlelady yields back.
 I now recognize the gentlelady from Iowa, Dr. Miller-Meeks.
 Ms. Miller-Meeks. Thank you, Mr. Chairman. And I want to 
thank our witnesses for testifying before this subcommittee 
today.
 There are many topics, such as prior authorization, which 
we just heard about, and denial of claims, which the majority 
of which are later approved without modification, that I would 
like to discuss with our witnesses today. But unfortunately, or 
fortunately for you all, I only have 5 minutes, so I am just 
going to jump in.
 As a physician and veteran and a former director of public 
health, I strongly support innovation in healthcare delivery, 
but every dollar wasted on inefficiency, waste, denial of 
claims, or unnecessary billing is a dollar not spent on patient 
care.
 That is why Senator Grassley's recent report detailing 
UnitedHealth Group's conduct in the Seniors Health Insurance 
Advantage plans, commonly known as Medicare Advantage, that 
report is very troubling. I have had many doctors within the 
State, and I myself have experienced what is happening when 
patients go--or patients come back after having visited at 
home.
 Medicare Advantage was created to improve outcomes and 
coordinate care for seniors, not to incentivize gaming the 
system.
 Do any of your companies decide a claim for a level of care 
without documentation or justification for the level of service 
or test or imaging?
 The answer to that is no. You require documentation.
 The independent Federal oversight reports from HHS's have 
identified that conditions, including congestive heart failure, 
were among diagnoses often added via in-home assessments are 
chart reviews and Medicare Advantage.
 So if you would deny a claim from a provider without 
documentation, why is it that you feel at liberty to submit a 
claim to CMS for a diagnosis based on a home visit?
 Congestive heart failure is not a paperwork diagnosis. It 
is a serious, life-altering condition. And when it is added to 
a patient's record without active management, without their 
routine provider and doctor knowing that they have the 
condition, that is creating higher payment without 
accountability, and it is a danger to patients and providers.
 Now I am going to turn our attention to a lesser-known 
player in the healthcare system that I believe American people 
should be made aware of: PBMs and PBM GPOs. The largest PBMs--
CVS Caremark, Express Scripts, and Optum--have created rebate-
contracting entities or PBM group purchasing organizations, 
which are adding to the complex and opaque nature of the 
medicine supply chain.
 My first PBM reform bill on transparency was in 2019 as an 
Iowa State senator. PBMs claim these entities provide them and 
their clients with greater bargaining power to lower costs, but 
recent investigations by Members of Congress, industry experts, 
State attorneys general, and Federal oversight agencies suggest 
the opposite may be true.
 [Information displayed:]
 [GRAPHICS NOT AVAILABLE IN TIFF FORMAT]
 
 Ms. Miller-Meeks. We have a graph up here. Let's start with 
the left. The drugmaker, who pays rebates directly to the PBMs 
and PBM GPOs to ensure their drugs were included on their 
health plan formularies, meaning the drugs are covered by 
insurance. Then their PBMs, and their PBM GPO subsidiaries 
collect the rebates, which they promise to pass through their 
patients and health plans.
 Can any of you tell me what percentage of rebates are 
passed through to the patient who is paying a higher drug cost 
because the rebates are added to the price of the drug? Is it 
zero?
 You don't even know that you are not giving these patients 
back a rebate for paying higher drug prices.
 Next, the PBMs pass supposedly the rebates to the health 
plans. However, the health plans are told 100 percent of the 
rebates negotiated by its PBM are then returned to the plan as 
savings. They often aren't told anything about the PBM GPOs 
subsidiaries, which collect a whole different set of fees from 
the drugmaker in exchange for formulary management.
 So a health plan might be getting 100 percent of the 
rebates the PBM received, but the plan has no idea if the 
rebate got everything the GPO earned, or how much money the GPO 
may have kept.
 It begs the question, are PBM GPOs just a cover for the Big 
Three to say in a contract that they pass through 100 percent 
of the rebates they get, and also a way to keep anyone else 
from being able to fully access brand drugs?
 Mr. Joyner, on average in the commercial market, what 
percentage of manufacturer rebates and fees negotiated through 
your PBM are retained by your GPO, or are they going to other 
subsidiaries, or offshore?
 Mr. Joyner. Congresswoman, we pass through 99.9 percent of 
the rebates to our customers and feel really strongly about the 
strength of our purchasing arm. In fact, if you look at the 
branded products that were rebate----
 Ms. Miller-Meeks. I am going to reclaim my time.
 Mr. Cordani, how many of--your GPO are sent out as 
headquartered, why is it headquartered outside the United 
States, and do you pay taxes on fees in America?
 Mr. Cordani. Our GPO is headquartered in Switzerland. We 
are a global company, so we leverage our global infrastructure 
for that GPO----
 Ms. Miller-Meeks. Thank you.
 Before I yield my time, why isn't this a violation of 
Stark? As a physician, I cannot do what you all have done with 
PBMs.
 With that, I yield.
 Mr. Griffith. The gentlelady yields.
 I now recognize the gentlelady from Massachusetts, Ms. 
Trahan, for 5 minutes of questioning.
 Ms. Trahan. Thank you, Mr. Chair.
 Like all of my colleagues, I hear from people across my 
district who are exhausted by having to make impossible 
financial decisions about their healthcare while a handful of 
massive corporations post record profits and their top 
executives take home record pay.
 Your Republicans have destabilized hospitals and families 
with their biggest healthcare cut in American history and their 
failure to extend the ACA tax credits with no alternative plan 
to bring costs down.
 At the same time, the private insurance market itself has 
become deeply consolidated, and that consolidation is a major 
reason costs remain so high.
 You have sitting before us the executives from four 
companies that together control about 50 percent of the 
commercial insurance market. Not exactly a depiction of a 
healthy, competitive system. It is a system of haves and have 
nots, where market power is concentrated, competition is 
weakened, independent providers are squeezed out, and families 
are forced to pay more.
 The lack of real checks and balances is bad for patients, 
it is bad for innovation, and it is bad for affordability.
 And to show what this level of consolidation looks like in 
maybe a more familiar context because your business is deeply 
complicated, let's just step outside of healthcare for a 
moment.
 Imagine if in the auto market one dominant company didn't 
just sell car insurance, but they also owned the dealerships, 
controlled all the repair shops, and ran the claim systems--
meaning one company would be selling the cars, steering the 
repairs, and setting the price at every step. Independent shops 
would struggle to survive, consumer choice would shrink, 
innovation would be stifled, and basic economics tells us that 
prices would rise, not fall.
 Yet in healthcare, we have allowed insurance to buy up 
doctors, pharmacies, and critical infrastructure and build 
exactly this kind of vertically integrated ecosystem.
 If one car company sold the insurance, owned the 
dealerships, controlled the repair shops, and ran the claim 
system, regulators would immediately worry about steering, 
self-dealing and higher prices.
 So I will just kind of throw it out into the ether: Can 
anyone on this panel explain why consumers should believe 
healthcare is the one industry where this kind of corporate 
structure lowers costs instead of raising them?
 You know, I pose this question, it is a tough one, and it 
is obviously volunteered, because peer-reviewed research 
consistently shows that provider consolidation drives higher 
prices, especially for commercially insured patients. And those 
higher prices show up as higher premiums, higher deductibles, 
higher out-of-pocket costs, and higher overall spending.
 When an insurer owns the provider it pays, it can set 
internal reimbursement rates instead of negotiating in a 
competitive market, and that kind of consolidation has been 
shown to raise prices for the same services.
 Now, UnitedHealthcare is the country's largest private 
insurer and owns roughly 90,000 doctors through Optum, meaning 
a growing share of premium dollars are circulating inside the 
same company instead of lowering premiums or providing rebates 
to patients.
 Mr. Hemsley, as my colleague from Pennsylvania mentioned, 
UnitedHealth determines the reimbursement rates paid to Optum-
owned physician groups, and those rates that you set are inside 
the same corporate family, hidden from regulators, hidden from 
competitors, patients, us.
 So, Mr. Hemsley, when United owns the insurer, the doctors, 
the pharmacy benefit managers, and the care delivery system 
end-to-end, where exactly is the competitive pressure supposed 
to come from to keep prices down?
 Mr. Hemsley. Thank you for the question, and I think it is 
an important area to clarify. The structure of that is in 
response to the marketplace to actually drive more value and 
drive costs down by the integrating and allowing these elements 
of healthcare services to actually serve the consumer better. 
There is a great deal of oversight and regulation on the 
establishment of pricing within an organization like ours. All 
the sponsors of benefits evaluate and can look at those prices.
 Ms. Trahan. So respectfully, the claim that competitive 
pressure is keeping pricing down or that regulation is keeping 
down is undermined by the fact that the Department of Justice 
is actively investigating UnitedHealth over how its physicians 
and insurance divisions interact, including interviewing former 
Optum doctors.
 And the bottom line is this: When the same companies 
control the insurance, the doctor, and delivery of care, 
competition just breaks down and families pay more. What is 
clear right now is that this system is working very well for 
corporate profits, but this committee has a responsibility to 
fix a system that today isn't working for patients.
 Thank you. I yield back.
 Mr. Griffith. The gentlelady yields back.
 I now recognize the gentleman from California, 
Mr.Obernolte, for his 5 minutes of questioning.
 Mr. Obernolte. So we are having a discussion today about 
why health insurance costs so much and how we can better 
allocate ratepayer dollars to healthcare costs.
 Mr. Markovich, I was pretty astonished last year when I 
heard that Blue Shield had contributed half a million dollars 
to a committee supporting the passage of Prop 50 in California. 
Prop 50, as everyone in this room knows, was an effort to shift 
five congressional seats from Republican control to Democratic 
control. It is a pretty transparent partisan undertaking that 
passed.
 Reasonable minds can disagree whether or not that is 
something that should have been supported. I myself feel like 
midcycle redistricting erodes voters' trust in our elections 
and our democracy. I opposed doing it in Texas. I opposed doing 
it in California. Reasonable minds can have a discussion about 
that, but I was just astonished that a health insurance company 
would wade into a political debate in such an enormous way.
 Why on Earth did you do that?
 Mr. Joyner. Well, respectfully, Congressman, we didn't do 
that. What we did--we have a long history of Blue Shield of 
California contributing to candidates from both parties at the 
Federal and State level, including Governors Schwarzenegger, 
Brown, and Newsom, and we try to support candidates that we 
think will be thoughtful about healthcare policy.
 And this contribution to a fund that did not have a 
specified purpose is something we committed to as a part of 
that. After that contribution had happened, the Governor then 
purposed those funds for Proposition 50, and our plan did not 
take a position on it.
 Mr. Obernolte. OK. To be clear, though, these were two 
different checks for a quarter million dollars each to a ballot 
measure committee, not a candidate, I mean, we understand 
supporting candidates, but this was to support a ballot 
measure.
 So if not Prop 50, what ballot measure did you think you 
were supporting?
 Mr. Joyner. Well, we didn't know, neither we nor the other 
healthcare companies----
 Mr. Obernolte. You wrote a half-a-million-dollar check not 
knowing what ballot measure you were supporting?
 Mr. Markovich. We and other companies, including other 
healthcare companies, all contributed to this account, and it 
is not uncommon, particularly in California, with lots of 
propositions, where candidates would prefer contributions to 
these types of accounts as opposed to direct contributions to 
their campaign support.
 Mr. Obernolte. Well, now knowing what you know, do you 
regret having made that contribution? I mean, this was the 
only--Prop 50 was the only proposition that this committee 
supported.
 Mr. Markovich. Well, we did not support or oppose 
Proposition 50. We didn't take a position on that.
 So, you know, it is a decision we consciously made going 
in, as did others, and just didn't have control over where it 
went afterwards.
 Mr. Obernolte. All right. Well, let me--you, in your 
testimony, said that you think that our healthcare system needs 
some tough love. Respectfully, I would like to offer you some.
 When a health insurance company weighs in to such an 
obviously political topic like that, it not only erodes your 
ability to work with folks on the other side of an issue but 
also erodes consumers' trust in the system as a whole. So 
please don't do that again.
 Mr. Hemsley, I represent a very rural section of 
California, and one of the biggest problems we have is access 
to healthcare. So we are grateful to have critical access 
hospitals that are in most of the communities that I represent.
 But we are having an increasing problem with Medicare 
Advantage plans like the ones that you provide, where the 
critical access hospitals are no longer recognized as being in 
network, and my constituents are forced to drive long distances 
to get the healthcare they need.
 Now, I understand that keeping costs down is something that 
is often in tension with contracting with these hospitals. But 
let me also suggest that when people have to drive hours and 
hours to get access to basic healthcare, some of them just 
won't do it, and that denial of healthcare turns out to have 
much larger costs in the long term for our entire system.
 What can we do to improve that, and why are those decisions 
being made?
 Microphone, please.
 Mr. Hemsley. Thank you for the question, Congressman.
 There is meaningful pressure in the Medicare Advantage 
space given the funding actions taken in the previous 
administration that has put a great deal of pressure in terms 
of what can be served.
 We are very interested and dedicated to the rural 
healthcare and adequacy there. I will look into the situation 
that you describe.
 But we are also advancing initiatives to see if we can get 
rural care resources paid more effectively and more currently. 
So we have four pilots in the market that are expediting 
payment--trying to cut the payment timeframes in half. And----
 Mr. Obernolte. So, I am sorry, we are out of time here. But 
these critical access hospitals are going to close if this 
trend continues. That is not good for you, and it is not good 
for the constituents that rely on it.
 Mr. Hemsley. We appreciate that----
 Mr. Obernolte. I yield back.
 Mr. Griffith. The gentleman yields back.
 And we are in a dilemma. All of our witnesses have to be at 
another hearing in just a little bit. So, unfortunately, we are 
going to have to roll back the question time for Members to 3 
minutes subsequent to the questioning by Ms. Ocasio-Cortez, who 
is now recognized for 5 minutes.
 Ms. Ocasio-Cortez. Thank you so much, Mr. Chairman. And 
apologies if we have to move quickly here due to the time.
 Thank you to all of our witnesses for coming here today.
 Mr. Joyner, you are the CEO of CVS Health, correct?
 Mr. Joyner. Correct.
 Ms. Ocasio-Cortez. And I actually don't know how many 
Americans know this, but CVS Health owns Aetna, the health 
insurance company, correct?
 Mr. Joyner. Correct.
 Ms. Ocasio-Cortez. And CVS, which owns Aetna, also owns Oak 
Street Health medical clinics, correct?
 Mr. Joyner. Yes, it does.
 Ms. Ocasio-Cortez. And, in addition to that, they own, of 
course, CVS pharmacies. And CVS Health also owns CVS Caremark, 
the pharmacy benefit manager, which helps negotiate some of 
these rebates and prescription prices, correct?
 Mr. Joyner. That is correct.
 Ms. Ocasio-Cortez. And CVS Caremark processes nearly 30 
percent of all prescriptions in a given year. And so, in other 
words, CVS Caremark helps determine the prices that patients 
pay for a third of all prescriptions in the U.S.
 [Information displayed:]
 [GRAPHIC] [TIFF OMITTED] T3596.066
 
 Ms. Ocasio-Cortez. In fact, I was following one of CVS's 
recent--or, one of CVS's investor calls, where they really laid 
out quite clearly what this means if you are a patient. This is 
what is known as a ``captive'' strategy. And CVS, in the 
investor call, used the example themselves of a patient known 
as Kate.
 Kate has an Aetna health insurance plan, right here, which 
is owned by CVS Health. She then goes to a CVS pharmacy. She is 
connected to an Oak Street Health medical clinic. She sees a 
doctor at Oak Street Health who prescribes her medication. And 
then she goes to fill that prescription at a CVS pharmacy.
 So the price Kate pays for that medication is dictated by 
Aetna, CVS Caremark, and they also own the drug manufacturer 
Cordavis.
 Mr. Joyner, this is quite a bit of market concentration, 
wouldn't you agree?
 Mr. Joyner. No, I wouldn't agree that it is market 
concentration. I would suggest it is a model that works really 
well for the consumer.
 Ms. Ocasio-Cortez. Yeah. I think it works very well for 
CVS. I think--in fact, you all said on the call that a fully--
you all call it a ``fully engaged member,'' that is great 
marketing there--``a fully engaged member unlocks sizeable 
value for payors and CVS Health.''
 So the health insurance gets a cut, the pharmacy benefit 
manager gets a cut, the drug manufacturer gets a cut, and the 
patient gets screwed.
 I think the Federal Trade Commission has also found that 
healthcare conglomerates like CVS Health charge more for 
medications filled at their pharmacies. We are talking about 
thousand percent markups on medications for cancer and HIV.
 And, you know, I think this is actually an interesting 
point of common ground that I may have with some of our 
Republican colleagues here in this hearing, because, whether 
you are a blue-blooded capitalist or a card-carrying Democratic 
Socialist, I think corporate monopolies are a problem. And this 
vertical integration is destroying people's ability to access 
care.
 You know, I don't think--we are seeing this across the 
board. And if they can self-deal--you know, I saw something 
that was interesting from the opening statement of Mr. Hemsley 
from UnitedHealth talking about how much United spends--was it 
85 percent on care, Mr. Hemsley?
 Mr. Hemsley. Approaching 90 percent.
 Ms. Ocasio-Cortez. Approaching 90 percent. But the ACA 
forces you all to spend a decent amount of that on subsidies on 
care.
 But when you own the care, when the insurer owns the 
pharmacy, owns the PBM, owns the drug manufacturer, you also 
own the healthcare cost. You own a big chunk of the healthcare 
cost.
 And so, you know, 100 years ago we had this type of market 
concentration in our banks, and we did something about it when 
it crashed the economy, and we passed the Glass-Steagall Act. 
We should be considering that in our healthcare system.
 And if we believe in competition, I think we should put our 
votes and our legislation in alignment with that and consider 
breaking up this industry in order to allow the competition 
that prevents this kind of vertical integration and abuse of 
power.
 And, with that, I yield back.
 Mr. Griffith. The gentlelady yields back.
 I now recognize the gentleman from Oregon, Mr. Bentz, for 
his 3 minutes of questioning. Sorry.
 Mr. Bentz. That is fine, Mr. Chair. Thank you.
 Thank all of you for being here.
 I am going to follow Dr. Joyce in asking that each of you 
produce certain documents. But I am really interested in the 
float. And that, of course, is what leads to people calling 
insurers banks doing a side business as healthcare. Because, of 
course, you charge the premium, you collect the money, you put 
the money in the bank, it earns interest, and then you pay it 
out.
 And so the float is of extraordinary interest to those of 
us that support HSAs, because a health savings account means 
that, instead of paying the premium to you, the theory is, the 
person with the account earns the money.
 Starting with you, Mr. Hemsley, is that true?
 If HSAs were put into place, would the patients actually be 
earning the money instead of the insurance company?
 Your microphone.
 Mr. Hemsley. Sorry. Thank you for the question, 
Representative. I don't know if I understand the question, but 
we maintain----
 Mr. Bentz. No, then let's go back.
 Mr. Hemsley. Yeah.
 Mr. Bentz. It is simple enough.
 Mr. Hemsley. Uh-huh.
 Mr. Bentz. If HSAs were put in place and people could put 
their money into the HSA and have it earn interest from them 
instead of paying it to you as a premium, and they would wait 
until, I guess, they had the problem or the deductible to pay, 
would they be earning the money instead of you? That is the 
question.
 Mr. Hemsley. They earn interest rates in their HSA 
accounts.
 Mr. Bentz. Maybe a better way of asking this is shifting 
over to how much money an insurance company makes by denying a 
claim.
 So what I was doing up here as I was waiting for my turn to 
ask these questions, I was trying to determine how much money 
insurance companies would make while they delayed in making a 
payment on a claim that ultimately is approved. And I found it 
here. But in order to put it in proper perspective, one has to 
know how big the company is and what the total denied claims 
amount to.
 So I was looking at you because, unfortunately, you are 
first, for you. the total denied pool is 19 percent, a 19 
percent denial rate, which amounted to about $50 billion of 
your total income. How much interest did you earn on that?
 And I am going to ask--you don't have to answer now. I am 
going to ask that each one of you, though, answer that for me 
and for the committee. So please respond in writing, how much 
money is made during the period of time that the delay is 
occurring on claims that are ultimately approved? That is what 
I want to see.
 And maybe--because it is obvious, the argument, that if you 
deny a claim you get to earn money on the denied amount that 
you don't pay until you finally do have to pay it out.
 Now, you can argue about all the stuff you have gone 
through, and I was going through some of that here. In this 
case, I recognize those justifications. I want to see the 
amount. And that is what we are going to start with.
 With that, Mr. Chair, I will yield back.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentleman from Massachusetts, Mr. 
Auchincloss, for his 3 minutes of questioning.
 Mr. Auchincloss. This week, it looks like the House of 
Representatives is going to pass PBM reform finally, which is 
good news for patients. But it seems to me that the Big Three 
health insurance corporations, knowing that PBM reform is 
around the corner, needed a different way to retain profits 
while still on paper complying with new requirements and the 
coming requirements of PBM reform, and so they formed these 
group purchasing organizations overseas, in Ireland and 
Switzerland in particular, that have since been exhaustively 
investigated.
 And I will enter into the record, Chair, that 
investigation.
 Mr. Griffith. Date of the article?
 Mr. Auchincloss. January 6th.
 Mr. Griffith. Without objection--of this year?
 Mr. Auchincloss. Yes.
 Mr. Griffith. Without objection, so ordered.\1\
---------------------------------------------------------------------------
 \1\ The information has been retained in committee files and is 
contained in the Documents for the Record at https://docs.house.gov/
meetings/IF/IF14/20260122/118890/HMTG-119-IF14-20260122-SD003.pdf.
---------------------------------------------------------------------------
 Mr. Auchincloss. Now, this investigation found many, many 
things, but of note, particularly for UnitedHealth GPO Emisar, 
that although it had no website, no email, no phone number 
available at the time of the investigation, it was described as 
``negotiating rebate agreements with pharmaceutical 
manufacturers'' and was also bringing in tens of millions of 
dollars per employee.
 So what is going on over there?
 Mr. Hemsley, how many people does Emisar employ?
 Ms. DeGette. You need to turn on your mic.
 Mr. Auchincloss. Mic, please.
 Mr. Griffith. Turn on your mic.
 Mr. Auchincloss. Microphone, please.
 Mr. Hemsley. I am sorry.
 I don't have a specific answer, but several thousand.
 Mr. Auchincloss. Several thousand.
 And is the number of covered lives that Emisar covers 
different than the number of covered lives your PBM, Optum Rx, 
serves?
 Mr. Hemsley. I don't have the exact number, but I believe 
they serve other health plans and have a different----
 Mr. Auchincloss. That number is important, though, sir, 
because if your GPO is not serving more covered lives, how is 
it possibly aggregating purchasing power any more than the 
existing PBM?
 We are going to follow up with questions on the record, 
because these GPOs are an attempt to circumvent congressional 
authority over PBM reform, and they are ultimately going to be 
a source of profit, to the detriment of patients' copays.
 Mr. Hemsley, I want to pivot, actually, from policy to the 
personal, though.
 You and your company and your colleagues suffered a 
horrendous loss last year, and the reaction on social media to 
the murder of Brian Thompson was a shameful moment for this 
country, particularly for his sons, who don't deserve that.
 Would you like to state into the Congressional Record, 
which will last forever, unlike those social media posts, what 
kind of man Mr. Thompson was?
 Mr. Hemsley. Yeah. Thank you for the--for that opportunity.
 I think we can all disagree on many things, but I think one 
thing we can agree on is that violence or the threat of 
violence is not appropriate in any circumstances.
 Brian Thompson was a force for good. He was a creative and 
effective man in terms of trying to address many of the 
challenges that have been presented today. And we miss him 
dearly, and I appreciate the opportunity to recognize him.
 And he left two very fine men behind as his children, and a 
wife and a family. And I think that, as we bring things down to 
what is real in many of the conversations today, I appreciate 
you recognizing and giving an opportunity for that.
 Mr. Auchincloss. And may his memory----
 Mr. Griffith. The gentleman yields back.
 Mr. Auchincloss. I yield.
 Mr. Griffith. I now recognize the gentleman from Ohio, Mr. 
Balderson, for his 3 minutes of questioning.
 Mr. Balderson. I got that memo, Mr. Chairman. Thank you 
very much.
 Thank you all for being here.
 And since we are on 3 minutes, my first question is going 
to go to Ms. Boudreaux.
 Thank you for being here, ma'am.
 CMS internal data shows that, in 2021, the average 
percentage of enrollments in the ACA market without any medical 
claims was 19 percent. That percentage jumped to 35 percent in 
2024. I believe this was largely due to the enhanced COVID 
premium tax credits.
 Under the Biden administration, congressional Democrats 
approved billions of taxpayer dollars that went to your company 
with very little oversight. This lack of transparency in 
oversight led to rampant fraud and waste.
 What I find interesting is that the waste over the past 
several years seems to have been a much bigger issue in the 
Federal exchange than the State-based exchanges.
 Yes or no, Ms. Boudreaux, did your company see evidence of 
increased waste, fraud, and abuse since congressional Democrats 
enacted the temporary COVID credits?
 Ms. Boudreaux. Thank you for the question, Congressman.
 What we saw--again, we have real concerns, similar to you. 
We share the concern about fraud, waste, and abuse. And our 
enrollment comes directly from the Federal and State exchanges, 
and it was--you know, the enrollment there, we think, was about 
15 percent, not the 30 percent you were showing.
 Mr. Balderson. OK.
 And why was this waste more pronounced at the Federal 
exchange than the State-based exchanges?
 Ms. Boudreaux. Again, we saw--as we looked at that, we 
worked very closely with the State exchanges, but we did see 
some consistency between the Federal and State.
 But, again, we are incredibly focused and share your 
concern about fraud, waste, and abuse and support many of the 
guardrails in the marketplace program around authentication of 
enrollment, doing that in a much more significant way. And we 
also support continuous enrollment, because we think that 
allows for a healthy population.
 Mr. Balderson. OK.
 What are you seeing in the marketplace that makes stronger 
protections necessary?
 Ms. Boudreaux. So there are a couple of opportunities, we 
believe.
 One is verifying eligibility, ensuring that those who are 
eligible for the premium subsidies. We can do that with two-
factor eligibility.
 Again, only having special enrollment periods, really 
limiting those. Because, again, what makes a stable exchange 
marketplace is continuous coverage, policies that support that.
 We also believe that coverage and being able to have 
preventative services over the long haul really supports 
individuals in the exchange and helps us to manage healthcare 
costs.
 Mr. Balderson. Do you support legislation to strengthen the 
patient validation protocols?
 Ms. Boudreaux. Unfortunately, sir, I am not sure I know 
exactly what that legislation is. I am happy----
 Mr. Balderson. Well, we haven't done anything yet. I am 
just asking if you would support that. So, OK.
 Thank you very much.
 I yield back.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentleman from Louisiana, Mr. Carter, 
for his 3 minutes of questioning.
 Mr. Carter of Louisiana. Thank you, Mr. Chairman.
 We have heard in the lead up to this hearing again and 
again that my colleagues, if nothing more than in their action, 
have indicated that it is OK for 24 million Americans to see 
their healthcare premiums increase by 2 or 3 or even 4 times.
 The defense to this is--and I will quote one of my 
colleagues--is saying, ``Those 24 million people are just 7 
percent of Americans.''
 I suspect if you are one of the 24 million people 
experiencing skyrocketing healthcare cost, even financial ruin, 
that rhetoric doesn't really resonate with you.
 The people in my home district of Louisiana are, in many 
cases, hardest hit.
 Mr. Hemsley, can you share with me--there is an issue with 
this notion of step therapy, where a patient is forced to use a 
medication that may be a generic or may be something else that 
is used similarly, even though their physician has indicated 
they don't think that that is the best medicine for them.
 Should a licensed physician who knows the patient be 
trusted over an insurance algorithm when determining the most 
appropriate treatment instead of forcing patients through a 
step therapy requirement that delays care and oftentimes 
increases suffering and even cost?
 Mr. Hemsley. No, I think there are appropriate times for 
step therapy, but in the situation you describe I would not.
 Mr. Carter of Louisiana. And Mr. Joyner?
 Mr. Joyner. Yeah, I agree. Step therapy is an opportunity 
for one to introduce a savings opportunity for the consumer and 
member as well, so----
 Mr. Carter of Louisiana. But, respectfully, oftentimes it 
is not a savings, it is a nuisance.
 Because the physician is saying, ``This doesn't work for my 
patient.'' The patient goes to the pharmacy and is told, ``You 
can't get this because the insurance company won't approve it 
because you haven't tried this.'' And the patient says, ``But I 
have tried it. It doesn't work. There are horrible side 
effects. But now I have paid a 30-, 60-day, 90-day copay for 
it, and they won't let me do it again.''
 Isn't that unfair to a patient whose doctor--not an 
algorithm, but whose doctor has stated that this medicine 
doesn't work?
 Mr. Joyner. Yeah----
 Mr. Carter of Louisiana. These are the kind of things that 
we hear from our constituents, who are caught in the middle, 
trying to get a medication to assist them with their ailment, 
but only being caught up in the confines or the clutches of 
bureaucracy within healthcare.
 Mr. Joyner. Yep. We completely agree with you, Congressman. 
In fact, if they have tried and failed, that is exactly where 
we want to engage and where we want to work with the provider 
on the appropriate therapy.
 Mr. Carter of Louisiana. So is it fair, from all of the 
companies--I have 7 seconds--fair, from all the companies, that 
you agree that this is an issue and that you will commit to 
working with us to be that buffer for the patient so they are 
not caught up in a forced step therapy when the medicines don't 
work, to overrule their physicians, but to listen to them?
 Is that a ``yes''?
 Thank you.
 I yield.
 Mr. Griffith. I am seeing yeses from everybody, and I 
appreciate those questions.
 And I now look to recognize the gentleman from Ohio, Mr. 
Rulli, for his 3 minutes of questioning.
 Mr. Rulli. Thank you, Mr. Chair.
 And I want to take a moment and I want to thank 
Congressman--I am not sure if I can say his name--for calling 
out with Brian Thompson. He has always been in our prayers. And 
I think lowering the temperature and bringing things to a 
normal society is where we need to go, and there are definitely 
problems, and we are going to work on them.
 So, with that said, House Republicans, by passing the Big 
Beautiful Bill and Lower Health Care Premiums for All Americans 
Act, have made it clear that they are serious about lowering 
healthcare costs and expanding choice and improving the quality 
of care for all Americans.
 At a time when Americans are facing the highest healthcare 
costs in years, it is important, more than ever, to continue to 
bring down these costs.
 Passage of the ACA left Ohioans with less healthcare 
insurance and options and skyrocketing premiums.
 So I want to take a different approach. When I was in the 
Ohio Senate, I had this question for years, and I am going to 
bring it to you right now. To all the witnesses, do you believe 
that competition and free market leads to affordability?
 And what I mean by this is, under the ACA, patients are not 
allowed to shop their premiums across State lines. Patients who 
live near State borders cannot shop their plan for the best 
possible price on these plans. In my opinion, that could bring 
down the cost.
 What changes can Congress make to potentially allow 
interstate competition and increase the variety of plan options 
that patients can choose from?
 Anyone on the panel is welcome to answer.
 Mr. Hemsley. We would endorse all kinds of ideas and be 
open-minded about anything that could get bipartisan support 
for increasing access, reducing cost, making healthcare more 
affordable. If that was on--if that idea was part of that, we 
could be for it.
 Mr. Markovich. As a general principle, competition is good. 
What can get troubling or challenging for health plans is, 
there are a lot of State regulations around health insurance. 
And so, if they are different from one plan to another because 
they are based in a different State, that can create just a 
challenging environment to have apples-to-apples comparisons in 
terms of shopping for customers.
 But, overall, if you can increase choice and increase 
competition, that is a good thing.
 Mr. Rulli. Do you think that by us excreting this from the 
ACA, that would help? Or do you think, like, a freestanding 
bill to address this, where we could have interstate 
competition?
 Mr. Markovich. Congressman, I'd be happy to work with you 
on it. I don't--I am not trying to--I know the time is limited. 
It is a fairly complex question, to make sure that you are 
doing what you are intending to do, which is increase 
competition and consumer choice, without creating an 
environment in which it is misleading for consumers because 
what they are buying from one plan versus another is very 
different in terms of their coverage. And that could be an 
unintended consequence if it is not shaped the right way.
 Mr. Rulli. I would love those conversations, if possible.
 Thank you.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentlelady of Texas, Mrs. Fletcher, for 
her 3 minutes of questioning.
 Mrs. Fletcher. Thank you, Chairman Griffith.
 And thank you to all of our witnesses for being here today.
 I think we can all agree that we should be working to lower 
healthcare costs for all Americans. And I have heard from many 
of my constituents in Houston about the same problems that my 
colleagues have talked about today--in particular, prior 
authorization, which leads to delays in care, and about the 
incredible burden of the back-and-forth between providers.
 I represent so many physicians who come to me and tell me 
they are not able to give their patients the care that they 
need because of the amount of time that they spend and their 
staff spend on the phone fighting with insurance companies. 
These are huge issues that we absolutely have to address.
 I also think, with the limited time that we have, Congress 
hasn't helped yet either this year. Instead, this Congress has 
voted to decimate our healthcare system and raise costs for all 
Americans by cutting Medicaid funding and eliminating the 
enhanced premium tax credits that we have been talking about 
under the Affordable Care Act.
 Mr. Carter just touched on this, and Chairman Guthrie made 
an important point earlier, that not everybody participates in 
an ACA plan. But I think what we haven't heard as much of today 
is that this entire system is an ecosystem. And so all of the 
costs--the cuts to Medicaid, the cuts to the ACA premium tax 
credits, removing people from the risk pool--will mean that 
everybody else's costs are going to go up.
 That is a core principle of insurance, right? You get more 
people into the pool--this is the idea of the ACA--get more 
people in, you can bring costs down.
 So I think that that is something that we need to 
understand here as we are making policy going forward.
 And because, gosh, this is really limited time, I just want 
to go straight to: The Republicans have proposed, I think, two 
new things today. One of them is that they are suggesting 
putting money into HSAs.
 So I want to ask each of the insurance industry witnesses 
here: Yes or no, can HSAs be used by individuals to pay their 
health insurance premiums?
 I will start with you, Mr. Hemsley.
 Can you turn on your microphone, please?
 Mr. Hemsley. If that was part of a bipartisan solution----
 Mrs. Fletcher. But, today, can you use HSA funds to pay for 
your premium?
 Mr. Hemsley. No.
 Mrs. Fletcher. OK.
 Mr. Joyner?
 Mr. Joyner. No.
 Mrs. Fletcher. Ms. Boudreaux?
 Ms. Boudreaux. There is no single solution. HSAs would need 
to be expanded. But we do think there is an opportunity.
 Mrs. Fletcher. Thank you, Ms. Boudreaux.
 Mr. Cordani?
 Mr. Cordani. Structurally, no, but employers are able to 
use HSAs to complement catastrophic coverages, effectively, and 
perhaps we could learn from the employer market.
 Mrs. Fletcher. Mr. Markovich?
 Mr. Markovich. Under current law, no.
 Mrs. Fletcher. OK. And that is the key. Under current law, 
this isn't a solution, to just use the HSAs.
 The other question I have in general--well, we have 15 
seconds, so I am just going to submit some more questions for 
the record.
 But I thank you for your testimony today.
 And I will yield back.
 Mr. Griffith. The gentlelady yields back.
 I now recognize the gentleman from New York, Mr. 
Langworthy, for his 3 minutes of questions.
 Mr. Langworthy. Thank you very much, Mr. Chairman.
 And I will kind of cut right to the chase. I mean, this is 
my first term on the Energy and Commerce Committee, and I have 
had an awful lot of healthcare meetings, and some of you have 
been by the office. But I ask every stakeholder that comes, why 
is healthcare increasing so drastically compared to other 
facets of the economy? Who is at fault?
 And the amount of finger-pointing--you know, if the 
hospitals are there it is the insurance companies, or if it is 
the insurance companies it is because of pharma, if it is 
pharma it is because of the insurance companies.
 And we need to get to the bottom of why premiums have 
exploded on Americans over the last 10 years and more 
drastically in the last 2, and what is driving these costs.
 And what I think is important for us to be aware of is, 
what is each of your dedication to the bottom line with the--
the bottom-line cost to the taxpayer, to the consumer? Because, 
I mean, we are obviously shoveling trillions of dollars at the 
healthcare system in America, yet prices are exploding.
 Now, some of my colleagues want the Government just to pay 
for this for everyone, and that is what they think is the best 
ultimate solution. You heard several mention that. I believe in 
the American healthcare system that is a free-market system 
because I think it leads the way in innovation to get us the 
best outcome.
 So, Mr. Hemsley, what is UnitedHealthcare specifically, not 
generally, doing right now to lower premiums for its customers?
 Mr. Hemsley. Thank you, Representative, for the question.
 We are intensely focused on managing costs----
 Mr. Langworthy. You need to keep these answers short. I 
mean, is there a specific action you are----
 Mr. Hemsley. Managing costs, coordinating care, using data 
and insights and value-based care as the key to change the 
whole direction of healthcare towards a value-based outcome 
system and less towards a volume-based system.
 Mr. Langworthy. OK.
 Mr. Joyner, what is CVS specifically, not generally, doing 
to lower premiums for its customers?
 Mr. Joyner. Yeah. Today, we believe the single biggest 
issue is the health status of the population. They are aging, 
consuming more healthcare resources. So our focus is on 
wellness, prevention, keeping people out of the hospital, 
keeping people on low-cost therapies that we believe will 
ultimately manage the overall health cost, and, like 
UnitedHealthcare, focusing on an outcomes-based model with the 
provider. So we are working collaboratively and introducing 
technology to help bring the consumer into the process.
 Mr. Langworthy. Ms. Boudreaux?
 Ms. Boudreaux. Thank you.
 Congressman, we have two core strategies in our company: 
one, reduced overall healthcare costs, and simplify the system.
 I would offer three practical things.
 One is, as we have shared, improve and streamline the 
prior-authorization process to take complexity out of the 
system for members and care providers.
 Second, investing in fraud, waste, and abuse to take on 
necessary costs and make the premiums go to the right things.
 And the last thing, as I share with my colleagues, 
continuing to invest and paying for value in outcomes to make 
people healthier.
 Mr. Langworthy. OK.
 My time has expired, and so I will yield back, and if the 
rest could respond in writing, I would appreciate it.
 Mr. Griffith. The gentleman has yielded back.
 I now recognize Mr. Veasey from Texas for his 5 minutes--
or, 3 minutes. Excuse me.
 Mr. Veasey. Thank you, sir.
 I want to talk about vaccines, particularly because I think 
that Republicans and the Secretary, Secretary Kennedy, is 
undermining vaccines in this country.
 My home State of Texas, we are at the epicenter of the 
historic measles outbreaks, where we have seen 2,000 Americans 
and 2 Texas kids that have been killed unnecessarily. And 
measles, which were previously eradicated, is one of the most 
deadly diseases, but there is a safe and effective vaccine for 
that, and I think that we all know that.
 Meanwhile, 15 children have died during this flu season, 
and 90 percent of them were unvaccinated.
 So it is not theoretical. For decades, insurers have 
covered vaccines based on the recommendations of independent 
medical experts. Those recommendations have literally saved the 
lives of 1 million Americans since 1994.
 And, despite this fact, Secretary Kennedy has injected this 
pseudoscience into Federal vaccine policy and weakened the 
childhood immunization schedule. The Secretary says he wants to 
make America healthy again, but all he is doing is bringing 
measles back again. His actions have abandoned decades of hard 
scientific evidence and put children's lives directly at risk.
 And so I want to ask this. And I would just like to go down 
the line to each one of you, and we will start here, on my 
right here. Yes or no, as a CEO, do you commit to covering 
ACIP-insured vaccines on the immunization schedule prior to 
Secretary Kennedy's reckless changes for plan year 2026? And 
for what reason is your decision making that?
 If everybody could just go down the line, yes or no, do you 
plan on----
 Mr. Hemsley. So our----
 Mr. Veasey. And we don't have a lot of time. If you could 
just give a yes or no.
 Mr. Hemsley. Our coverages are comprehensive and supported 
by the same authorities you reference, and then we allow the 
consumer to make a choice as to how they want to proceed. So we 
provide comprehensive coverage. And that is between the doctor 
and the----
 Mr. Veasey. So you are still going to be covering?
 Mr. Hemsley. Yes, we are.
 Mr. Veasey. OK.
 Mr. Joyner. Congressman, no change to our policy. We are 
continuing.
 Ms. Boudreaux. Congressman, we cover vaccines. We haven't 
changed our policy. Our vaccines--we do it as required by law, 
but we also look at ACIP as well as clinical societies, and 
that is how we make our decisions.
 Mr. Cordani. Our comprehensive coverage remains intact, and 
it is largely zero-dollar cost to our customers in the employer 
market.
 Mr. Markovich. Yes. It is the consensus of the medical 
community that they are safe and effective, and so we continue 
to cover them.
 Mr. Veasey. Thank you.
 Well, first of all, let me just say thank you. We really 
appreciate that you are following the science behind all of 
this. And I am glad that we can agree that children's lives are 
more important than politics.
 And, again, not only are you following the science, I mean, 
you are following common sense. This stuff has been researched 
and it has been a part of American life and has made us safer 
for a reason. So thank you for your commitment.
 I yield back.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentlelady from Florida, Mrs. Cammack, 
for her 3 minutes.
 Mrs. Cammack. Thank you, Mr. Chairman.
 You know, over and over, I hear the same question from 
people back home: Why in the heck am I paying for insurance if 
it actually doesn't cover anything?
 And this is across all plans and companies. So, to be 
clear, I am not just talking about the Obamacare, which has 
dominated much of the conversation today. Only, you know, 20 
million people are covered there. But what I am talking about 
are the 160 million Americans who get their coverage through 
employer-sponsored insurance. And that is where so many of the 
affordability challenges are showing up every single day.
 And these families are rarely talked about. They haven't 
been talked about much today. And so I want to address their 
concerns that they have sent to me across social media, emails, 
text messages--thousands and thousands of messages we have 
collected over the last 72 hours.
 And there is a very troubling theme: One, they think that 
you guys showing up here today will change nothing. So, on 
behalf of the thousands and thousands--hell--millions of 
Americans, please take this hearing as a moment in time when 
you need to change direction.
 I am going to make this very simple for people watching 
back home. I am going to ask a series of questions, and if this 
statement applies to your company, please raise your hand.
 So, if your executive compensation at your company, 
including yours, is primarily tied to financial performance, 
like revenue, margins, earnings, or stock price, please raise 
your hand.
 Don't be shy.
 OK. I see three out of five. OK.
 Raise your hand if your compensation is directly tied to 
patient health outcomes, such as preventing harm from delays, 
reducing inappropriate denials, or ensuring access to care--the 
majority of your compensation is tied directly to patient 
outcome.
 I am going to submit for the record right now a request 
that you in writing give us the fine print of your contracts, 
displaying where patient outcome is directly tied to your 
executive compensation.
 Raise your hand if an executive at your company takes a 
financial penalty when a patient is harmed due to an insurer-
caused delay or wrongful denial.
 OK. No hands. So no one at the company bears any 
responsibility for denial of care or patient outcomes.
 Raise your hand if an overturned denial or appeal 
negatively impacts executive compensation at your company.
 Not one.
 That right there is the problem. When denials and delays 
and appeals, which happen every single day, occur, the patient 
and their families are the ones that get hurt, not your bottom 
line.
 I also heard very briefly from our colleague that HSAs 
currently cannot pay premiums for plans. Good news is that 
there is legislation called the ACCESS Act, which would allow 
for HSAs to expand and use that subsidy to pay for those 
premiums. So I look forward to working with her on this 
legislation.
 I see my time has expired. With that, I yield.
 Mr. Griffith. And the gentlelady yields back.
 And I now recognize the gentlelady from Illinois, Ms. 
Kelly, for her 3 minutes of questioning.
 Ms. Kelly. Thank you, Chair Griffith and Ranking Member 
DeGette, for holding today's hearing.
 There is a healthcare affordability crisis in this country 
under President Trump. Republican-led cuts to Medicaid will 
drive the uninsured rate up by roughly 50 percent over the next 
decade. At the same time, their refusal to extend ACA tax 
credits will more than double monthly premiums for millions of 
Americans.
 You have heard all this already.
 The result is simple: People will delay care or go without 
entirely because they cannot afford coverage, as our witnesses 
said.
 These are people's lives we are talking about. As some of 
the largest health insurance administrators in the Nation, you 
have real influence over Federal policy and industry outcomes. 
The ask has been clear, and your responses have not met the 
moment.
 For all CEOs: Back in November, one of my constituents, 
Mercedes Wells, had a traumatic birth in her car after being 
discharged from the hospital while in active labor. In 
response, I announced a new maternal health bill, the WELLS 
Act. I also sent letters to many of you asking about your 
commitment to maternal health.
 We have a maternal health crisis in this country, and 
evidence shows that doulas lead to better healthcare for 
pregnant women.
 So I ask all of you: Raise your hand if your company has a 
standard policy to explicitly cover doulas for their services 
during and after pregnancy for the majority of your plans.
 All but one. Thank you.
 Mr. Hemsley, earlier, you admitted to my colleague that 
your company uses technology in a number of initiatives.
 Over the last 5 years, there has been an alarming increase 
in reports of inappropriate AI prior-authorization denials by 
your company. One study in 2024 found that these AI denials had 
a 90 percent error rate. If a healthcare provider had this bad 
of an error rate, they would lose their license and be in jail.
 Does United use AI or algorithmic tools to adjudicate 
claims or pretreatment estimates? And what governance and 
independent auditing do you use to prevent systemic 
underpayment or inappropriate denials?
 Mr. Hemsley. Yes. Thank you for the question.
 We use AI solely for administrative purposes. We do not use 
it for clinical applications at all.
 Ms. Kelly. So it has nothing to do with denials?
 Mr. Hemsley. Only from an administrative--gathering 
documents, things like that. Only administrative.
 Ms. Kelly. Will you pledge that each determination will be 
reviewed or--I don't know how you do it--by an outside, 
neutral, practicing physician who is licensed in the same 
specialty as the care in question?
 Mr. Hemsley. I am not sure I understand what you are 
asking.
 Ms. Kelly. I guess I am questioning why people are denied, 
and you are saying it is not by AI.
 So who determines how people are denied?
 Mr. Hemsley. Clinical policies, broadly accepted and 
promulgated by the care community, the academies and colleges--
--
 Ms. Kelly. So not physicians in the field, or yes?
 Mr. Hemsley. Physicians oversee our clinical reviews.
 Mr. Griffith. Ms. Kelly.
 Ms. Kelly. I am sorry.
 Mr. Griffith. That is all right. If we didn't have a time 
limit, I would let you go.
 I recognize the gentleman from Texas, Mr. Crenshaw, for 3 
minutes.
 Mr. Crenshaw. Thank you, Mr. Chairman.
 You know, since the Affordable Care Act passed, premiums 
have increased 129 percent. That is 90 percent more than 
inflation. In the 10 years before the ACA passed, premiums rose 
at about 5 percent per year, 69 percent total, which roughly 
tracked inflation.
 Something broke the system, and that something is 
Obamacare. So what happened?
 Now, the Democrats who passed the ACA deserve blame. They 
deserve a lot of blame. They imposed rigid mandates and 
regulations that made it nearly impossible to offer flexible, 
affordable, tailored insurance plans. That crushed competition.
 Much of this is government's fault, but not all of it. In 
your testimonies, many of you claim vertical consolidation is a 
major driver of rising costs, like it is outside your control. 
But is it?
 Because here is the thing: Many of you here today are 
participants in that consolidation. We have insurers that own 
physician groups, PBMs, hospitals, pharmacies--every rung of 
the healthcare ladder. And the result? Competition is basically 
nonexistent. Many counties have one or two ACA plans, options, 
if that.
 Your companies have narrowed networks so severely that 
patients are forced into the very consolidated systems that you 
now complain about. And the Government did not force you to do 
that.
 So, look, Congress has a responsibility here to fix a 
broken system, to fix incentives, restore patient control and 
choice and competition. But you have a responsibility to also 
act in good faith.
 Premiums are way up. Profits are way up. Claim denials are 
way up, which was just addressed. One in five claims denied. It 
is an all-time high this year. Why? That is a rhetorical 
question, because I don't have enough time.
 But I do want to ask one simple question. Wouldn't it make 
a lot more sense to subsidize low-income patients--which is the 
point of the ACA, right, subsidize low-income patients directly 
through a health savings account that they own instead of 
subsidizing you, the insurance companies?
 Who can answer that one? Anybody?
 Does anybody agree with that, that concept? Subsidize 
patients through a health savings account instead of 
subsidizing insurance companies?
 Mr. Markovich. Congressman----
 Mr. Crenshaw. Not even our patient advocate?
 Sorry. Go ahead.
 Mr. Markovich. I don't want to--did you want to-- OK.
 I am--I and we are very open to having mechanisms where 
money goes directly to----
 Mr. Crenshaw. OK, I got one ``maybe.'' Anybody else?
 Mr. Hemsley. We would be supportive of anything that puts 
the consumer more in control.
 Mr. Crenshaw. I got another ``maybe.''
 Mr. Hemsley. And----
 Mr. Crenshaw. Sorry. There is no time.
 Mr. Hemsley [continuing]. Funding makes no difference. It 
is the costs.
 Mr. Crenshaw. Got it.
 Patient advocates even?
 Mr. Allen. Respectfully, I think that could undermine the 
healthcare system----
 Mr. Crenshaw. Interesting. OK. ``No.''
 So let me ask you again another question, just Econ 101. 
Does competition re--competition requires real choice, right?
 This is an Econ 101 question. Competition lowers prices, 
doesn't it?
 Competition will exist if patients control the money and 
then can go on the market and actually make you compete with 
each other.
 Mr. Griffith. Mr. Crenshaw, would you submit that for the 
record, please?
 Mr. Crenshaw. I will.
 Geez, that was fast.
 Mr. Griffith. Yeah, I know.
 The gentleman yields back.
 I now recognize the gentleman from Ohio, Mr. Landsman, for 
his 3 minutes.
 Mr. Landsman. Thank you, Mr. Chair and the ranking member, 
all of you for being here.
 In my lifetime, a lot has happened, but the biggest thing, 
in my mind, is the extreme concentration of wealth and power. I 
think most of the issues that we face in this country can be 
connected back to this concentration of wealth and power at the 
top.
 And nowhere is that more true than in healthcare. CEO pay 
across the board is up a thousand percent since I was born. 
Workers are, you know, up 25 percent. They can't keep up. And 
as it relates to healthcare, you have one of three Americans 
who are struggling with medical debt. One in three Americans 
had to pass on a needed procedure because they couldn't afford 
it.
 And in the One Big Beautiful Bill, after decades of all of 
this money going up, they voted on the largest transfer of 
wealth in American history from low-income working folks to the 
super-wealthy, spending trillions of dollars on tax cuts for 
the super-wealthy, and they cut a trillion dollars in 
healthcare.
 So folks are sitting here wondering, you know, how is this 
possible? How do I, as a hardworking American, continue to be 
screwed over like this?
 Now, looking at the profits: United, over the last couple 
years, it is on average around $20 billion; CVS, around $6 
billion; Elevance, around $6 billion; Cigna, around $6 billion.
 You all know this is an issue. It is why UnitedHealth said, 
``We are going to invest these ACA profits back into our 
customers.''
 If shareholders said tomorrow, ``Let's do this, let's do 
more of this, this was a good idea, let's invest more of our 
profits back into our patients,'' what would you tackle first?
 So you have got $15 billion, $14 billion, this year in 
profits. Let's say you just want to keep a couple, shareholders 
said, ``The rest of it is going back into our patients.''
 Would it be medical debt? Would you focus on denying less 
claims? Would you cover more people?
 I am just curious--and we will start with Mr. Hemsley--what 
would you invest in first?
 Mr. Hemsley. Thank you for the question, and I think it is 
very thoughtful.
 And the same things we are investing in now: the 
advancement of a movement towards value-based care to get off 
the volume; better systems and technology to take the 
complexity and make the system more simple.
 I think those things would profoundly change the underlying 
costs and the consumer and care provider experience.
 Mr. Landsman. I only have 12--but I would love to hear from 
everyone else, but I only have 10 seconds. I want to be 
respectful, because you guys have to go to another meeting.
 We have a lot of work to do. Congress has to fix this. They 
have to fix the healthcare system so that we can invest more in 
patients. I think this is an opportunity for you all--and you 
are hearing it--to do the same.
 Thank you. I yield back.
 Mr. Griffith. The gentleman yields back.
 I now recognize the gentlelady from Indiana, Mrs. Houchin, 
for her 3 minutes.
 Mrs. Houchin. Thank you, Mr. Chairman.
 And thanks to the witnesses.
 Today's hearing provides us an opportunity to look beyond 
the premiums and examine what is happening behind the scenes, 
how insurers structure administrative fees, how payment 
practices affect employers and providers, and whether current 
incentives are aligned with affordability for patients or 
profits for insurance companies.
 There are so many perverse incentives created by the ACA, I 
honestly can hardly blame you for trying to find ways to 
increase profits. But vertical integration, I think, is 
something that we absolutely have to take a look at, and I am 
glad this committee is doing that.
 As insurers have become more vertically integrated and 
increasingly relying on administrative entities like group 
purchasing organizations--and a reminder: Vertical integration 
is the insurance companies owning the providers, owning the 
hospitals, owning the pharmacies, owning the PBMs, and now 
affiliating with group purchasing organizations.
 GPOs were created by the largest PBMs and have added yet 
another layer of complexity to the prescription-drug supply 
chain, making it even more opaque. Two of the three largest 
PBMs have established their GPOs overseas, which you have 
confirmed, while continuing to claim that rebates and fees are 
being negotiated on behalf of U.S. plan sponsors and patients.
 Evidence suggests, in practice, some of these entities may 
be retaining rebates in the commercial market and charging 
additional fees that are not passed on to employers or 
reflected in lower out-of-pocket costs at the pharmacy counter. 
And with vertical integration, it makes the true profit margins 
easier to hide.
 In fact, a recent investigative report published by 
Hunterbrook looked into PBM GPOs and found that, while there 
were fewer than 150 employees across all three of them, PBM-
owned GPOs somehow generated more than $50 million in revenue 
per employee. Not even Nvidia generated that level of per-
employee revenue.
 So my question is, how are PBM GPOs so incredibly 
profitable?
 Anyone can answer.
 How is it so profitable to have a GPO? How are they 
profiting $50 million in revenue per employee on the backs of 
American patients?
 No answers. OK.
 I have also heard from a number of physicians who have 
reported concerns about the No Surprises Act and the 
implementation of that often delaying awarded amounts.
 And I want to focus quickly on Elevance Health.
 Ms. Boudreaux, compliance--do you track compliance 
internally on those arbitration awards?
 And how many of those are remaining unpaid or partially 
unpaid more than 30 days after a favorable decision?
 Ms. Boudreaux. So, Congresswoman, thank you for the 
opportunity to talk about the No Surprises Act.
 We are very supportive of the No Surprises Act, always have 
been. There is a problem, though, in the arbitration system, 
where private equity and EC-backed entities are flooding the 
system. The CBO recommended that 17,000, roughly, would be this 
year. We have received, across the system, almost 2.2 million 
arbitrations.
 And because of the style of arbitration, where it is 
basically baseball-style, we are seeing awards at 429 to 450 
percent.
 And if you would just give me 1 second, I think making this 
real for people is so important.
 You know, in this situation, Los Angeles is one of the 
areas we are seeing the highest arbitration awards. CMS for 
spinal surgery will pay $1,500. Commercial insurance will pay 
$1,900----
 Mr. Griffith. And, ma'am----
 Ms. Boudreaux [continuing]. Offering $2,000----
 Mr. Griffith [continuing]. We are pushing up against your 
time. We know you have another hearing.
 Ms. Boudreaux. Thank you. I will just finish with----
 Mr. Griffith. So please do a full explanation in your 
written response to Mrs. Houchin.
 Mrs. Houchin. And, Mr. Chairman, I have a number of 
questions that I will provide to the record.
 Mr. Griffith. Absolutely.
 Mrs. Houchin. Thank you for the time.
 Mr. Griffith. The gentlelady yields back.
 I now recognize the gentleman from Michigan, Mr. James, for 
up to 3 minutes.
 Mr. James. Thank you, Mr. Chairman.
 We were promised affordable care. What Americans got was 
unaffordable premiums, sky-high deductibles, and bureaucrats 
standing between patients and their doctors, all while American 
people get sicker.
 I said back in 2018 that Obamacare was a flawed, broken 
system, and I was called a fearmonger.
 So let's stop arguing about intentions and talk about 
results. Under this system, families are punished if they stay 
healthy and they are financially devastated if they get sick. 
That is not healthcare, that is sickcare.
 Since the Affordable Care Act passed, wages are up 26 
percent, but deductibles are up 160 percent. Premiums are up 
nearly 80 percent. The average family now pays around $24,000 a 
year for health insurance--more than many families pay for 
their mortgage. Some are paying $30,000, $40,000 and still 
rationing care. That is not a safety net, that is a hangman's 
noose.
 So let's start with a very simple question for some very 
smart people here. Raise your hand if you believe that 
healthcare today is affordable for the average American.
 No hands. So we have agreement.
 I believe it is unaffordable because nobody knows what they 
are paying for. The only way we can have affordability in this 
country is if we have accountability. And we, you all must be 
accountable to the American people. President Trump made this 
clear in his Great Healthcare Plan: You must post your prices 
so patients can see them.
 So I will ask you again plainly: Yes or no, if you are 
buying a plane ticket, do you know how much it costs?
 Yes, you know how much it costs. So why in healthcare do we 
hide our prices? You only hide things if you don't want people 
to know what you are doing.
 Will you commit--will you commit to publishing clear, 
complete rates, side-by-side coverage comparisons, that 
employers and families can actually understand in the same 
places that you place your bills?
 I see one head nodding.
 Mr. Markovich. Actually, we are already doing that.
 Mr. James. Already doing it?
 Mr. Markovich. Yeah.
 Mr. Hemsley. Already doing that.
 Mr. James. It is not having the desired results. We need to 
do better. We need to stand behind the transparency data with 
the same seriousness that you expect patients to pay you back.
 The American people were promised affordable care. What you 
have given them is higher costs and worse health outcomes. 
After more than a decade, Americans are a heck of a lot sicker 
and a heck of a lot more insured at the exact same time. How 
does that happen?
 Your incentive structures must change. You must be held 
accountable, and you must change course. The American people 
are done with it. I am done with it.
 And I am speaking to all my colleagues on this committee. 
We have to hold these companies accountable, and the best way 
to do this is through transparency. My bipartisan and bicameral 
Patients Deserve Price Tags bill does exactly that. Please, 
give the American people your support.
 Thank you, Mr. Chairman.
 I yield.
 Mr. Griffith. The gentleman yields back.
 That concludes the questioning section of this hearing.
 I ask unanimous consent to insert in the record documents 
included on the staff hearing document list and those that were 
brought up during the meeting.
 Without objection, so ordered.\1\
---------------------------------------------------------------------------
 \1\ The information has been retained in committee files and is 
contained in the Documents for the Record at https://docs.house.gov/
meetings/IF/IF14/20260122/118890/HMTG-119-IF14-20260122-SD003.pdf.
---------------------------------------------------------------------------
 I now recognize the ranking member for 30 seconds for a 
point of personal privilege.
 Ms. DeGette. Thank you, Mr. chairman.
 I just want to thank everybody for coming here, and I want 
to thank you in advance for being part of our bipartisan 
solution. We appreciate it.
 Our Members worked hard for this hearing, and they wanted 
to ask their full 5 minutes of questions. So I would just ask 
everybody--we had to truncate the end of it because of your 
schedule. So I would just ask everybody, when you get these 
questions from Members on both sides of the aisle, please give 
us in-depth responses quickly, because it will help us as we 
work to develop bipartisan legislation.
 Thank you, Mr. Chairman. I yield back.
 Mr. Griffith. Thank you, Ranking Member DeGette.
 I would like to thank all of our witnesses again for being 
here today.
 Members may have additional written questions for you. I 
guarantee they will. And I will remind Members, they have 10 
business days to submit questions for the record, and I ask the 
witnesses to respond to the questions fully and promptly.
 Members should submit their questions by the close of 
business on Thursday, February 5.
 Without objection, the subcommittee is adjourned.
 [Whereupon, at 1:23 p.m., the subcommittee was adjourned.]

 [all]